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ABSTRACT

Angelman Syndrome (AS) is a rare genetic and neurologic disorder affecting
approximately 1 in every 15,000 people. This disorder is characterized by seizures,
absence of speech, motor and cognitive deficits, ataxia, and notably an abnormal happy
demeanor with frequent smiling and laughter. A neuron-specific loss of function of the
maternal allele of UBE3A, encoding for an E3 ubiquitin ligase, leads to the manifestation
of AS. There are currently no cures for AS and few therapeutic options to abate
symptoms. Although much investigation is required, research using the null mutation AS
mouse model suggests a plausible case for pharmacological intervention.
Major caveats of current mouse models includes strain influences and
phenotypic inconsistencies. There is a high demand for an AS model that consistently
recapitulates the majority of human phenotypes. With advancements in CRISPR/Cas9
technology, we have successfully created a novel AS rat model comprised of a full
deletion of maternal UBE3A. The mouse model only contains a deletion in exon, which
means it could potentially still generate a small N-terminal fragment of UBE3A. Western
blotting of our rat model brain and peripheral tissues indicates the UBE3A deletion is
pervasive with almost a complete loss in the CNS and about a 50% reduction in
peripheral tissues. The AS rat model displays normal breeding ability and Mendelian
distribution with no significant weight gain, unlike the mouse model which has significant
vi

weight gain compared to litter mate controls. The AS rat recapitulates many aspects of
AS, including significant deficits in motor coordination (increased hind limb clasping,
rotarod, and DigiGait) learning and memory (fear conditioning and digital touchscreen),
and deficits in social approach. These deficits in learning and memory tasks, are most
likely due to significant deficits in synaptic plasticity. Using hippocampal
electrophysiology (CA1-CA3) we demonstrated that this AS model has deficits in their
input/output curve, long-term potentiation (LTP) and well as long-term depression
(LTD). These data are consistent with the existing mouse model and further supporting
for this new AS rat as a good model for human AS.
Lack of an established AS biomarker has been detrimental in patient diagnosis
as well as testing the efficacy of novel therapeutics. With the creation of this rat model,
biomarker research has garnered significant interest, in part due to the rat’s larger size.
Here we report for the first time that Ube3a is present within cerebrospinal fluid (CSF) of
wild type rats but is absent in the AS rat. This observation was largely due to easier
sampling of sufficient CSF from a rat compared to mouse. We subsequently observed
similar results in the mouse model and human CSF.
Following the discovery that Ube3a is located in the CSF, we next investigated if
Ube3a is within the extracellular space of the hippocampus. Due to the deficits in
learning and memory paradigms as well as synaptic plasticity, we focused on the
hippocampus. Hippocampal microdialysis revealed Ube3a is indeed located within the
extracellular space. Utilizing the ubiquitination assay that involves a well-known Ube3a
substrate, S5A, we demonstrated that extracellular Ube3a maintains its E3 ubiquitin
ligase activity. This activity also included its ability to self-ubiquitinate. Although the
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function of Ube3a ligase activity extracellularly is unknown, we speculate that it may
have a functional role in synaptic strength and stability.
Previous reports have demonstrated intracellular Ube3a is under activitydependent regulation with a significant increase in mRNA levels after exposure to the
adverse learning task, fear conditioning. This increase suggests a dynamic involvement
of Ube3a in learning and memory. This lead us to hypothesize that secretion of Ube3a
into the extracellular environment may also be a dynamic process in learning and
memory. To test this idea, we used microdialysis on wild-type rats in conjunction with
fear conditioning exposure. Our results demonstrate that extracellular Ube3a is under
activity-dependent regulation with a significant increase in secretion of Ube3a at ~2 h
after the adverse learning task. This increase was maintained for at least 3 h after
induction, which may indicate a role in memory consolidation.
To further support the idea that extracellular Ube3a plays a role in learning and
memory, we applied exogenous Ube3a to AS rat hippocampal slices during LTP
recordings. We demonstrate that the deficits in LTP observed in the AS rat are rescued
to WT levels with exogenous Ube3a application. This is a significant finding, because
Ube3a appears to have multiple roles in different cellular compartments, but here we
demonstrate for the first time that Ube3a’s activity at the synapse is likely the most
important role of Ube3a in synaptic plasticity and learning and memory.
In summary, we have developed a novel rat model of AS which recapitulates
many important aspects of the human condition, including motor deficits, learning
deficits and electrophysiology deficits. Utilizing this novel AS rat model we are the first
to report the presence of Ube3a in the extracellular space and demonstrate its potential
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as an AS biomarker. This is the first report to show extracellular Ube3a is under activitydependent regulation and has the ability to recover LTP deficits. This new AS rat model
should offer avenues for increased exploration of AS and advance our understanding of
molecular targets of Ube3a, thus expanding our knowledge of the disease. This model
offers a high potential utility for drug evaluation, biomarker discovery, and will aid in the
development and testing of novel therapeutic treatments.
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CHAPTER ONE:
INTRODUCTION

1.1 History of Angelman Syndrome
An English physician, Dr. Harry Angelman, published a case study in 1965
describing three children with unique characteristics and distinct features associated
with central nervous system (CNS) impairment (Angelman 1965). Dr. Angelman titled
the study “Happy Puppet Syndrome” due to specific traits, which persist in cases today,
including outbursts of laughter and abnormal jerky movements. Following publication,
the syndrome was nearly forgotten until the late 1980s when the underlying
chromosomal region 15q11.2-q13 was discovered and believed to be responsible for
the manifestation of this disorder (Magenis et al. 1987). “Happy Puppet Syndrome” was
later renamed Angelman Syndrome (AS) in remembrance of Dr. Harry Angelman. While
this disorder is rare, affecting approximately 1 in 10,000-20,000 individuals, the
symptoms are severe and lifelong with potential for progression (Williams, Driscoll and
Dagli 2010).

1

1.2 Genetic Causes of AS and associated phenotypes
AS is a neurogenetic disorder caused primarily by alterations within the
maternally inherited allele for UBE3A, which encodes an E3 ubiquitin ligase. In
peripheral tissue, there is biallelic expression of UBE3A, with an ~ >50% reduction of
protein expression in AS patients. However, in the CNS, UBE3A undergoes neuronspecific imprinting and transcriptional silencing of the paternal allele with an antisense
transcript (Meng, Person and Beaudet 2012). The paternal allele is active during
development and then is silenced within mature neurons leading to predominant
maternal UBE3A expression within the brain (Judson et al. 2014). Thus, maternal
disruption of UBE3A results in a >95% reduction of neuronal UBE3A protein within the
CNS, leading to the manifestation of AS.
Approximately 70% of AS patients have a genetic alteration compromised of a de
novo deletion within 15q11.2-q13 on the maternal chromosome. Additionally, imprinting
defects of the maternal copy can inhibit UBE3A expression (6%), paternal uniparental
disomy (3%), and various mutations of the maternal chromosome (13%) can also be
responsible for the disorder. AS patients with large deletions demonstrate the most
classical and severe symptoms of AS. While deletion of UBE3A alone can lead to AS,
deletion of additional genes within the 15q11-13.3 locus can modify disease severity
(Clayton-Smith and Laan 2003; Williams et al. 2010). In most instances genetic
anomalies are sporadic albeit in approximately seven percent of AS cases, familial
reoccurrence has been reported (Moncla et al. 1999). Despite the profound and
penetrant symptoms in human AS, there are no gross anatomical aberrations noted in
either the AS human or AS mouse model brain (Jiang et al. 1998; Williams et al. 2010).

2

AS children present with symptoms as early as 6 months of age, gradually
becoming more apparent by 12 months old, albeit many can remain undiagnosed for
years (Williams et al. 2010). Many neurological AS symptoms are non-specific and
overlap with a wide variety of disorders, thus confounding diagnosis. AS is
characterized by severe phenotypes in both the CNS and periphery, all of which are
commonly associated with other disorders: absence of speech, non-ambulatory (~10%)
or abnormal gait, deficits in both fine and gross motor skills, seizures, sleep
disturbances, gastrointestinal issues, and intellectual disabilities ( Williams et al. 2010:
Clayton-Smith and Laan 2003). To distinguish AS from other central nervous system
(CNS) disorders, hallmark behavioral and neurological phenotypes are used, including
but not limited to, hyperactivity, fascination with water, an overall happy demeanor with
bouts of excessive laughter, and distinct electroencephalogram (EEG). Despite the
severity of these symptoms, most patients live a normal life span. Although with age
some phenotypes become exacerbated. Many AS patients who were ambulatory
commonly have a decline in their physical condition as they age, developing a more
severe ataxic gait eventually becoming wheelchair bound. This mobility decrease is
regularly due to limb hypertonicity and development of thoracic scoliosis (Clayton-Smith
and Laan 2003). Distinct facial features such as marked mandibular prognathism and
pointed chin become more prominent with maturity and seizures can become more
pronounced (~25% adults). With age, anxiety tends to become much more prominent
manifesting as increased self-harm and tantrums, tics and tremors, and cyclic vomiting (
Prasad et al. 2018; Larson et al. 2015; Thibert et al. 2013; Giroud et al. 2015). While
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many AS patients can non-verbally communicate, and few can perform small daily
tasks, this disease requires constant medical care.
Seizures are the primary reported reason for patient hospitalization and are a
leading cause of death in AS patients (Valente et al. 2006; Williams et al. 2010; Thibert
et al. 2013; Pelc, Cheron and Dan 2008). Seizures generally arise between the ages of
1 and 3 in AS patients and often display resistance to common anti-epileptic drugs. The
most common types of seizures reported are atypical absence seizures, infantile
spasms, myoclonic seizures, and generalized tonic-clonic ( Thibert et al. 2009; Pelc et
al. 2008; Valente et al. 2006). AS large deletion patients tend to present with increased
seizure susceptibility due to deletions of the non-imprinted GABA receptor subunit
genes (Minassian et al. 1998). This type of chronic epilepsy has been linked to
progressive memory impairment with significant hippocampal damage (Sutula et al.
1995; Hermann et al. 2002; Helmstaedter et al. 2003; Aldenkamp and Arends 2004).
The quality of life of these individuals is heavily impacted by the severity, frequency, and
intractability of the seizures (Thibert et al. 2013).
EEG abnormalities have recently been used for AS diagnosis. An abnormal EEG
often precedes clinical features and has distinct traits (Valente et al. 2006). The most
common EEG abnormality in patients is delta rhythmicity especially in the frontal
regions. It can also include one or more of the following: persistent rhythmic theta
activity and spikes or strong waves, mixed with 3-4Hz components of high amplitude,
usually within the occipital region (Boyd, Harden and Patton 1988; Laan and Vein 2005)
Sleep disorders are very common in AS patients with irregular sleep-wake
cycles, sleep movement disorders, hyperactivity, and early awakening (Clayton-Smith
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and Pembrey 1992; Didden et al. 2004; Pelc et al. 2008). Despite the lack of sleep, the
daytime routine of AS patients is not affected suggesting a diminished need for sleep
(Clayton-Smith 1993). This could also be confounded by other severe associated
phenotypes masking the consequences of sleep deprivation. During night time sleep
EEG recordings suggest AS children have decreased sleep efficiency as well as
reduced levels of REM sleep (Miano et al. 2004). Individuals with AS also display fewer
and shorter sleep spindles with an increased long range EEG coherence in the gamma
band (den Bakker et al. 2018).
There are currently no treatments to cure AS, and few therapeutic options are
available to abate symptoms. Current therapies are symptomatic and do not address
the underlying etiology, and these current symptom-based therapies have little to no
empirical support. There is no standard of care or approved treatment and given the
high burden of this disease, drug therapies resulting in even a small improvement would
be clinically and financially important to these families (Wheeler, Sacco and Cabo
2017).

1.3 UBE3A codes for an E3 ubiquitin ligase
In 1997, UBE3A was determined to be the critical gene responsible for the
manifestation of AS ( Matsuura et al. 1997; Kishino, Lalande and Wagstaff 1997; Trent
et al. 1997). UBE3A, also known as E6AP, an E3 ubiquitin ligase, and is located on
human chromosome 15. The most well documented and researched function of UBE3A,
is its role within the 26S proteasome pathway. The ubiquitin-proteasome system is a
pathway to regulate the degradation of proteins relying on ubiquitin, a 76 amino acid
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protein that is covalently attached to specifically targeted substrates. This is a multistep
process involving 1) an ATP dependent E1 ubiquitin-activating enzyme, 2) transfer of
the activated ubiquitin to the ubiquitin-conjugating E2 enzyme, 3) attachment of ubiquitin
to targeted substrate via an E3 ligase or E2-E3 complex, 4) elongation of the polyubiquitin chain, 5) transport of the poly-ubiquitinated substrate to the 26S proteasome,
6) and finally the degradation of the protein via proteasome contained ATPase subunits
and deubiquitinating enzymes (Hershko, Ciechanover and Rose 1979; Ciechanover et
al. 1981; Hershko, Ciechanover and Rose 1981; Haas and Rose 1982; Hershko et al.
1983). The most canonical form of ubiquitin attachment is K48 poly-ubiquitination,
where the chain of ubiquitin’s is formed by attaching subsequent ubiquitin’s to the lysine
48 residue on the previous ubiquitin. UBE3A exclusively forms K48-linked poly-ubiquitin
chains (Kim et al. 2007). The polyubiquitin chain acts as a clock in a sense that once a
protein has been around long enough and obtained enough ubiquitin’s (a chain of at
least 4 K63-linked residues), the protein is sent to the 26S proteasome for degradation
(Ikeda and Dikic 2008).
Currently there are only two known E1 enzymes, approximately 40 E2 enzymes,
and more than 600 E3 ligases (George et al. 2018). E3 ligases are divided into groups
based on their catalytic domain; Ring-Between-Ring (RBR), Really interesting new gene
(RING), or Homologous to E6-AP Carboxyl Terminus (HECT). UBE3A contains a HECT
domain, with a highly conserved catalytic C-terminus which harbors an active cysteine
where it can directly accept ubiquitin forming an ubiquitin thioester intermediate. It will
then directly transfer the ubiquitin to a Lysine residue on the N-terminus of target
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substrate or to an existing multi-ubiquitin chain, rather than acting as an adaptor protein
(Scheffner, Nuber and Huibregtse 1995).

Figure 1.3.1 Ubiquitin-proteasome pathway. 1) an ATP dependent E1 ubiquitin-activating enzyme
activates a ubiquitin 2) transfer of the activated ubiquitin to the ubiquitin-conjugating E2 enzyme 3)
attachment of ubiquitin to targeted substrate via an E3 ligase or E2-E3 complex 4) elongation of the polyubiquitin chain 5) transport of the poly-ubiquitinated substrate to the 26S proteasome when enough
ubiquitins have been accumulated 6) degradation of the protein via proteasome contained ATPase
subunits and deubiquitinating enzymes.

1.4 UBE3A mouse isoforms
Alternative splicing of the first eight exons gives rise to three known isoforms of
UBE3A differing in their N-terminus (Yamamoto, Huibregtse and Howley 1997). The
protein localizes in both pre and post synaptic neuronal compartments and in both the
nucleus and cytoplasm. Isoform one has nuclear localization while isoform two has
cytoplasmic localization. Isoform three is found in both the nucleus and cytoplasm.
Isoform two is the full length protein while isoforms one and three are lacking 21 amino
acids at the N-terminus. Isoform one utilizes an alternative polyadenylation site lacking
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87 amino acids within the HECT domain and is considered E3 ligase deficient. It has
been reported that mice lacking nuclear isoform three demonstrated all behavioral
phenotypes of the AS mouse model while mice lacking the cytoplasmic isoform two did
not display abnormalities.(Avagliano Trezza et al. 2019) This trend also carried over into
electrophysiology studies demonstrating that nuclear isoform three is the most crucial
for the development of AS related pathophysiology. This finding suggests that
transcriptional regulation might be a more pertinent function than UBE3A’s role in
protein degradation.

1.5 Parental imprinting of paternal UBE3A
Chromosome 15 q11-q13 is an epigenetically regulated region with several
genes being expressed exclusively from the maternal or paternal chromosome.
Neurons exclusively express UBE3A from the maternal allele due to an evolutionarily
conserved epigenetic mechanism. This mechanism is only present within neurons, with
glial cells maintaining biallelic expression within the CNS (Yamasaki et al. 2003; Dindot
et al. 2008). Due to differential methylation patterns on the maternal and paternal
Prader-Willi imprinting center (PWIS), the paternal allele is silenced via a large (>600bp)
non-coding antisense RNA transcript (UBE3A-ATS). The exact mechanisms behind
how this antisense transcript silences paternal UBE3A is unknown. There are two
competing models hypothesizing the mechanism, the complex formation model and the
collision model. In the complex formation model it is believed that the antisense strand
forms a degradable complex with the UBE3A transcript. Recently, the collision model
has gained more traction with growing support. In the collisions model, it is thought that
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while paternal UBE3A and the antisense strand are simultaneously undergoing
transcription, the polymerases run into each other knocking one another off the strand.
It has been demonstrated that there is a very small truncated 5’ transcript made from
the paternal allele, at similar levels of maternal UBE3A. Approximately at intron 4 of
UBE3A, both transcripts (paternal UBE3A and UBE3A-ATS) were found to be
decreased leading to the idea that around intron 4, both polymerases collide terminating
transcription. To further support this model, a transgenic mouse model was created
forcing UBE3A-ATS transcription to stop before reaching the UBE3A gene which
resulted in biallelic expression of UBE3A (Meng et al. 2012).
Due to AS patients have an intact paternal allele, which could theoretically
compensate for the loss of maternal UBE3A, an appealing therapeutic target has been
blocking the paternal UBE3A-ATS. Reports have demonstrated that the paternal
UBE3A-ATS can be removed either pharmacologically or genetically within AS mouse
models. Unfortunately this cannot be done in human patients due to toxicity, lack of
specificity or methodological limitations. Unsilencing the paternal allele using a genespecific therapy, antisense oligonucleotide (ASO), is proving to be a more promising
treatment which could translate into the human population (Meng et al. 2015).
A recent report has demonstrated that within the cortical circuits, the maternal
and paternal genomes are not functionally equivalent. Maternal UBE3A has a specific
role in the visual cortex before and after the critical period, specifically in experience
dependent alterations of cortical circuits. It also remains unclear if the paternal allele
would be able to express the same isoforms as maternal UBE3A and maintain the same
functions as its maternal counterpart (Sato and Stryker 2010). Although unsuccessful in
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humans thus far, reactivating the paternal gene still remains a promising therapeutic
target to abate certain phenotypes.

1.6 UBE3A is dose dependent
Loss or multiplication of genes within the 15 q11-q13 region do not go unnoticed.
Paternal deletion of this region leads to Prader-Willi syndrome while maternal loss leads
to the manifestation of AS (Cassidy et al. 2012). Conversely, duplication of maternal
UBE3A, doubling the amount of UBE3A within the CNS, leads to the most common
form of autism (Dup15q syndrome) (Copping et al. 2017). Prader-Willi syndrome and
AS can also arise from an imprinting error or uniparental disomy resulting in gene
expression from a single parental chromosome (Williams et al. 2010). UBE3A is tightly
regulated by three known mechanisms. 1) As mentioned previously, UBE3A undergoes
neuron-specific imprinting postnatally. During development both the maternal and
paternal genes have approximately 50% expression of UBE3A. Postnatally the paternal
allele is silenced and the maternal allele increases expression to compensate for the
loss of paternal UBE3A (Judson et al. 2014). 2) UBE3A can also regulate itself via selfubiquitination in its active form as an oligomeric complex by an intramolecular transfer
of ubiquitin from its active cysteine to one of its own lysine residues. UBE3A is
frequently found as its own target mediating its own degradation (Kao et al. 2000;
Zaaroor-Regev et al. 2010). 3) The final known mechanism is inhibition of UBE3A via
Protein Kinase A (PKA) phosphorylation on T485 (Yi et al. 2015).

10

1.7 Null-mutation AS mouse model
Studies conducted on the AS murine models have made major contributions to
researchers understanding of the mechanisms behind the manifestation of the AS
condition. Ube3a is located on murine chromosome 7 and demonstrates imprinting
patterns similar to humans. There are three known AS mouse models, all having
notable challenges including, but not limited to, strain influences, phenotypic
inconsistency, and loss of phenotypes with age (HS et al. 2013; Born et al. 2017). The
most commonly used AS mouse model was produced through an exon 2 null mutation
in 1998 (Jiang et al. 1998). This mouse model recapitulates many phenotypes
associated with human AS and remains the most widely used model for testing
therapeutic strategies. This AS mouse model was originally created on the 129/SvEv
background although historically, the C57BL/6 has been the leading background for
behavioral analysis therefore the AS mouse model was expanded to the C57BL/6
background (Crawley et al. 1997; Bach et al. 1995). There are four main phenotypes the
mouse model demonstrates, depending on background strain, that are also prevalent in
the human condition: cognitive disturbances, increased seizure propensity, synaptic
plasticity deficits, and motor coordination deficits (Huang et al. 2013; Born et al. 2017).

1.7.1 Motor coordination and behavioral deficits
Motor coordination deficits are prominent within all human AS patients ( Williams
et al. 2010; Clayton-Smith and Laan 2003). Many locomotor abnormalities and hallmark
behavioral traits can be recapitulated in a mouse model such as hyperactivity, abnormal
gait, anxiety, sociability, ultrasonic vocalizations and deficits in learning and memory
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tasks. The AS mouse model exhibits globally impaired motor coordination, making it a
suitable model for studying motor aberrations in AS. Hind limb clasping has been a
well-documented phenotype associated with the AS mouse model and has been shown
to be indicative of cerebellar ataxia. Motor deficits in rotarod, beam balance, wire hang,
as well as gait analysis have all been consistently reported (Egawa et al. 2012; Heck et
al. 2008; Meng et al. 2013; Jiang et al. 1998; van Woerden et al. 2007).
Due to the cerebellum being a prevalent component of motor functioning, many
studies have focused on potential cerebellar malfunctioning leading to the notable
ataxia seen in AS. Although it is pertinent to mention that the origin of motor deficits in
AS is still unclear, UBE3A is highly expressed in other sensorimotor areas such as the
striatum and motor cortex. The first publication characterizing pathological features
within the cerebellum of AS patients was based on an autopsy of an AS patient. The 21year-old woman demonstrated cerebellar atrophy, extensive Bergmann gliosis,
accompanied by loss of Purkinje and granule cells. These finding implicated the
cerebellum playing a crucial role in AS pathophysiology (Jay et al. 1991). Due to the
major contribution Purkinje cells have to motor functioning providing the sole output of
the cerebellar cortex, as well as expressing high levels of UBE3A, these cells were
heavily studied to determine if they were an underlying cause of locomotor deficits in
AS. It was reported that there are fast oscillations coupled with increased Purkinje cell
firing rates (Cheron et al. 2005). It has also been shown that there is a dysregulation of
the mTOR pathway resulting in alterations in Purkinje cell morphology (Sun et al. 2015).
Rapamycin treatment reinstates the mTOR pathway to normal functioning and was
shown to recover motor deficits in the AS mice. The mTOR pathway has been shown to
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be dysregulated in other portions of the AS brain and the observed pharmacological
rescue of motor deficits could also be attributed to other brain regions (Sun et al. 2016).
It has been reported within cerebellar granule cells that there is decreased tonic
inhibition and increased GAT1, a transporter of GABA from the synaptic cleft. Using a
GABA receptor agonist, 4,5,6,7-tetrahydroisothiazolo-[5,4-c]pyridine-3-ol (THIP), the
excitability of granule cells was decreased and the ataxic phenotype was recovered in
the AS mouse (Egawa et al. 2012). However, the tasks used to determine this recovery
are not specific to cerebellar dysfunction and the origin of motor deficits needs to be
further investigated. Conversely, a recent study examined the effects of ablating
cerebellar Golgi cells to determine if impaired tonic inhibition underlies locomotor
deficits in AS mice. Results indicated only transient ataxia demonstrating this altered
pathway is an unlikely candidate (Watanabe et al. 1998). A recent report has
demonstrated strong evidence against locomotor deficits arising from cerebellar origin.
Utilizing the cerebellar-specific vestibule-ocular reflex (VOR) paradigm, Bruinsma
(2015) demonstrated that cerebellar function is only mildly impaired (Bruinsma et al.
2015). This report further examined synaptic plasticity and action potential firing of
Purkinje cells and found that deficits usually correlated to cerebellar learning
impairments did not exist. Furthermore, they specifically deleted UBE3A within Purkinje
cells and found cerebellar learning or locomotion to be unaltered.
Although there are cerebellar alterations, the deficits are mild and not likely the
sole reason for the severe ataxic phenotype. Recent reports have demonstrated a
deficit in grey matter within many brain regions of AS patients and interestingly, within
the basal ganglia. Many AS patients display non-epileptic tremors which can be
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ameliorated with Levadopa, a commonly prescribed Parkinson’s disease therapeutic.
Furthermore, recent AS animal studies demonstrate abnormal nigrostriatal and
mesolimbic pathway signaling and a deficit in instrumental conditioning, a striatumdependent task (Riday et al. 2012). Interestingly, Ca2+/calmodulin-dependent protein
kinase II (CamKII) phosphorylation has been shown to be increased in the striatum of
AS mice and has been reported to be a regulator of dopamine D3 reeptors as well as
the dopamine transporter (Fog et al. 2006; Padmanabhan, Lambert and Prasad 2008;
Liu et al. 2009). These results signify the attribution of aberrant dopaminergic signaling
and are proposed as a major component underlying the dyscoordination, abnormal
movements, and tremors in AS individuals. Overall there may not be a single pathway
causing locomotor deficits, there may be multiple sites of dysfunction and global
synaptic alterations.
The AS mouse model has deficits in hippocampal dependent learning and
memory, reported in fear conditioning as well as Morris water maze (Jiang et al. 1998).
The learning deficits demonstrated in these tasks can be mild and results are not
consistent across laboratories. A recent report showed AS mice have a deficit in
behavioral extension, an operant active learning behavioral paradigm, which heavily
relies on prefrontal circuits (Sidorov et al. 2018). In Morris water maze, AS mice display
slower swim speeds and with less distance travelled. Preferences in light-dark tests,
lack of novel object preference, increased thigmotaxis in open field and elevated plus
maze all demonstrate anxiety phenotypes are common in the AS mice (Huang et al.
2013; Born et al. 2017). Hypoactivity is commonly reported during tasks such as open
field, however this is not necessarily similar to human AS. AS mice also display deficits
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in social interaction unfortunately opposing what is seen in human AS patients (
Williams et al. 2010; Clayton-Smith and Laan 2003).
AS humans lack speech entirely with few being able to verbalize simple words.
Most rely on communication via gestures or communication devices such as word
boards (Clayton-Smith and Laan 2003). It has been reported that within temporal
pathways associated with language, social, and cognitive functioning, AS patients have
a deficit in white matter indicating a decrease in axonal myelination (Peters et al. 2011).
Mice have rudimentary striatal-cortical circuits which are similar to human circuits
controlling production of learned vocalizations. Interestingly in the AS mouse model,
there is an increase in vocalization. The researchers within this study used new born
mice which could reflect innate behavior at birth instead of providing insight in to speech
acquisition and vocal learning deficits in human AS patients. This phenotype is highly
dependent on background strain and conclusions varied across publications (Jiang et
al. 2010; Mandel-Brehm et al. 2015).
There are many underlying pathologies that have been implicated in causing
such severe learning and memory deficits seen within the human AS population. A
recent finding reports an increase in all-trans retinoic acid signaling in the hippocampi of
AS mice. UBE3A is a coactivator of type I steroid hormone receptors, including
androgen, progesterone, estrogen, and glucocorticoid receptors (Ramamoorthy and
Nawaz 2008). UBE3A binds estrogen receptors leading to dimerization and
translocation to the nucleus collectively regulating the transcription of the Cyp26b1
gene, an enzyme responsible for degrading retinoic acid (El Hokayem, Weeber and
Nawaz 2018). With a decrease in Cyp26b1 expression, retinoic acid accumulates
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affecting overall cognitive functioning. Oxidative stress and altered mitochondrial
functioning are thought to also contribute to disruptions in cognitive functioning. AS mice
have significantly smaller mitochondria with increased superoxide and free radical
production within the CA1 of the hippocampus ( Santini et al. 2015; Llewellyn et al.
2015; Su et al. 2011). MitoQ 10-methanesuflonate (MitoQ), a mitochondria specific
antioxidant rescued deficits in fear conditioning as well as hippocampal synaptic
plasticity in the AS mouse (Llewellyn et al. 2015). A growing number of studies have
implicated UBE3A in the development of neuron structure. Deficits in UBE3A leads to
alterations in spine and dendritic morphology, with variability in head size and spine
length as well as an overall decrease in spine density (Dindot et al. 2008). Furthermore,
within the dentate gyrus of the hippocampus in AS mice, there is a significant
impairment in adult neurogenesis (Mardirossian et al. 2009). All of these reports
demonstrate how the lack of UBE3A has global impacts affecting overall cognitive
functioning

1.7.2 EEG abnormalities and seizure propensity
As mentioned above, one of the most devastating phenotypes in the AS humans
are severe seizures which occur in roughly 80% of patients (Williams et al. 2010). It is
important for AS models to display seizures to understand the underlying molecular
mechanisms behind their manifestation as well as potential therapeutics. AS patients
also exhibit hallmark penetrant electroencephalographic (EEG) abnormalities with
increased delta activity, persistent theta activity, and spikes and sharp waves (Williams
et al. 2006; Thibert et al. 2013). Depending on the background strain, the mouse model
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demonstrates audiogenic and increased susceptibility to chemically-induced seizures as
well as epileptiform EEG polyspikes, with increased delta power (Huang et al. 2013;
Born et al. 2017).
Increased excitability is a common feature in AS mice although, the exact
mechanism underlying the hyperexcitability is unknown. There is an overall imbalance
between excitatory and inhibitory processes that could contribute to seizure
susceptibility. Excitatory neurotransmission onto neocortical L2/L3 pyramidal neurons is
significantly decreased with inhibitory drive being even more so diminished (Wallace et
al. 2012). This could potentially arise from defective presynaptic cycling within
interneurons. It was recently discovered that targeted loss of UBE3A within GABAergic
neurons led to enhanced seizure susceptibility as well as increases in neocortical EEG
delta power. This leads to the idea that loss of UBE3A in GABAergic neurons is the
principal underlying pathogenic factor for AS hyper-excitability.
EEG studies have also demonstrated the AS mouse model demonstrates mildly
impaired sleep/wake cycles (Colas et al. 2005). The mice did not have altered circadian
rhythmicity but they did have disrupted sleep homeostasis (Ehlen et al. 2015). Recent
reports have identified BMAL1, a protein essential for the mammalian circadian clock, is
a ubiquitinylation target of UBE3A. This report demonstrated UBE3A acts as a key
modulator of the circadian system affecting amplitude, period and entrainment kinetics
(Shi et al. 2015).

1.7.3 Alterations in hippocampal synaptic plasticity
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Deficits in long-term potentiation (LTP) are a hallmark phenotype within the AS
murine model mentioned above (Jiang et al. 1998). Deficits in UBE3A can alter dendritic
spine development within the pyramidal neurons of the hippocampus and cortex as well
as cerebellar Purkinje cells. There are notable pathways affecting spine development
which are severely disrupted in AS. UBE3A is a negative regulator of Ephexin 5, a
guanine nucleotide exchange factor, whose role is the activation of RhoA (Margolis et
al. 2010). Activation of RhoA leads to the suppression of excitatory synapses leading to
a decrease in spine density. UBE3A negatively regulates mTOR1, a protein important in
cellular metabolism, regulation of translation, and LTP (Man et al. 2003; Sui, Wang and
Li 2008). Following loss of UBE3A, there is an increase in mTOR1 leading to an
increase in ARC, a protein responsible for AMPA receptor internalization severely
affecting synaptic plasticity (Sun et al. 2016). MTOR2 is negatively regulated by mTOR1
and is responsible for actin polymerization. Alterations in actin polymerization are
thought to be a leading cause of synaptic plasticity deficits. Treatment of AS mice with
Rapamycin, a mTORC1 inhibitor, completely reversed the imbalances in mTOR
signaling and ameliorated spine morphology, LTP, fear conditioning deficits, as well as
actin polymerization (Sun et al. 2016).
There are other pathways affected by UBE3A deficits such as small-conductance
potassium channels (SK2) receptor endocytosis. SK2 is critical for rhythmic activity and
sleep as well as learning and memory (Adelman, Maylie and Sah 2012; Ohtsuki et al.
2012). The SK2 receptor is a direct target of UBE3A and is involved in the regulation of
NMDA receptors. When there is an increase in SK2 receptors there is a decrease in
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NMDA receptor activation leading to severe impairment of LTP in the hippocampus. All
of these pathways heavily effect postsynaptic functioning during LTP.
While there are many reports about postsynaptic deficits, recent reports have
demonstrated alterations in pathways critical for presynaptic functioning in AS. Brain
derived neurotrophic factor (BDNF), a protein that instructs gene expression and protein
synthesis underlying LTP and memory formation, has been shown to have signaling
deficits due to the increase in ARC expression in AS (Cao et al. 2013). It has also been
demonstrated there are alterations in intrinsic membrane properties of the CA1
hippocampal pyramidal neurons, the initial segment of axons involved in the regulation
of neuronal output are significantly larger (Hallengren and Vaden 2014). The voltage
gated sodium channel NA+/K ATPase is significantly increased within the axons of AS
neurons causing an increase in the action potential threshold. The overall vesicle size
and vesicle number presynaptically released is decreased in AS. All of these studies
demonstrate how critical UBE3A is in both pre and post synaptic functioning.
While there are many pathways affected, studies have demonstrated that by
altering a single pathway, LTP deficits in the AS mouse can be recovered. Reactivation
of the BDNF pathway via a positive AMPA receptor modulator or NSI-189 phosphate (4benzylpiperazin-1-yl)-[2-(3-methyl-butylamino)pyridine-3-yl] methanone has recovered
plasticity deficits (Liu et al. 2019). In AS, there is an increase in ErbB4/NRG1 signaling
enhancing GABAergic neuronal CA1 inhibition. Inhibiting ErbB4 recovered LTP deficits
(Kaphzan et al. 2012). Decreasing the expression of a Na+/K ATPase α1 subunit
increased AS potentiation to WT levels (Kaphzan et al. 2013).
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While electrophysiology is a very helpful technique for identifying impaired
pathways for long-term potentiation in the hippocampus, it does not completely
recapitulate all the mechanisms required for learning and memory. While these
treatments can recover the synaptic plasticity in a very controlled setting, it doesn’t
necessarily translate to a therapeutic for the human population.

1.7.4 Issues with current AS mouse models
As mentioned previously, the majority of human AS cases (~70%) arise from a
large deletion of the maternal Ube3a gene. The previous AS mouse model is limited to
a null mutation on exon 2 not encompassing the majority of human AS manifestation
(~13%) (Jiang et al. 1998; Williams et al. 2010). A very prominent issue with this mouse
model is strain influences. There are different behavioral, EEG activity, and seizure
phenotypes depending on which background strain was used (Huang et al. 2013; Born
et al. 2017). When screening therapeutics, there is no single AS mouse model that can
be used to perform a comprehensive study encompassing all of the phenotypes
associated with the AS mouse. Researchers need multiple animals, with different
backgrounds, to inspect different aspects of AS making this financially draining. More
concerning is the loss of phenotype over a number of generations. This requires
rederiving the line from the Jackson Laboratory, which further adds to the cost of
producing these AS mice. Despite different background strains, all of the AS mice are
shown to have significant weight gain compared to their wild type littermates. While this
is seen in a small subset of humans with AS, it is not demonstrated in the majority of the
human AS population.
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1.8 Activity-dependent regulation of UBE3A in AS mouse model
Greer (2010) previously reported intracellular UBE3A being under activitydependent control (Greer et al. 2010). In primary neuronal culture there is a significant
increase in UBE3A expression in response to glutamate receptor activation or
membrane depolarization. Conversely, when activity is blocked, there is a significant
decrease in UBE3A levels. This occurs in both the nucleus and cytoplasm. It has also
been reported that following exposure to a novel environment, there is a significant
increase in UBE3A expression (Greer et al. 2010). Furthermore, during kainite-induced
seizures, there is an increase in UBE3A. Our lab previously demonstrated that during a
learning and memory paradigm, fear conditioning, there are region specific expression
profiles in a time-dependent manner. It was determined that both the maternal and
paternal allele follow the same expression patters within specific brain regions (Filonova
et al. 2014). All of these examples demonstrate that UBE3A is under activity-dependent
regulation implicating UBE3A in learning and memory

1.9 UBE3A in neurological diseases
Ubiquitination by UBE3A has many roles outside of the proteasome pathway.
Ubiquitination can lead to cleavage of proteins, cellular trafficking, activation of proteins,
transcription regulation, and phosphorylation (Ikeda and Dikic 2008; Li and Ye 2008).
Due to UBE3A s transient interaction with substrates, identification of interacting
proteins has been difficult. Although, many reported substrates of UBE3A have a wide
array of roles and major implications in AS pathology, including but not limited to, the
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microcephaly protein ASPM, mTORC1, Ephexin 5, and SK2 receptors (Greer et al.
2010; Singhmar and Kumar 2011; Sun et al. 2016). While targeting proteins for
proteasome degradation is UBE3As most understood role, recent reports demonstrate
UBE3A having many functions outside of ubiquitination, as well as implications in the
manifestation of many severe cognitive disorders, other than AS, such as Dup15q
syndrome (mentioned above), Alzheimer’s disease, Parkinson’s disease, Huntington’s
disease, and Schizophrenia.
In Alzheimer’s disease, dysfunction of UBE3A has been shown to precede
hallmark pathogenesis. Deficits in UBE3A lead to accumulation of ARC and Ephexin-5
leading to an activation of RhoA and GLuR1 internalization, culminating in pruning of
synapses (Olabarria et al. 2019). N-terminal huntingtin (Htt) misfolding induces
neurodegeneration in Huntington’s disease. Studies demonstrate aging-dependent
levels of UBE3A alter ubiquitination and degradation of Htt fragments contributing to
neurotoxicity of mutant Htt (Bhat et al. 2014). Salimen (2019) recently conducted a
study phenotyping a large population of individuals with schizotypal traits demonstrating
an increased dosage of UBE3A could be an underlying cause (Salminen et al. 2019).

1.10 Benefits of rats versus mice in studying neurological disorders
Traditionally, rats have been the preferred model of human disorders due to
greater similarities. Rats were once the most widely used species in medical research.
This led to a more extensive characterization of the rats physiological systems involved
in learning and memory making the rat more superior to mice in this aspect (Ellenbroek
and Youn 2016). One major issue that arose with the rat species was the lack of
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techniques for genetic manipulation. There have been many technological advances in
recent years giving researchers the ability to manipulate the rat genome in the same
manner as the mouse, allowing scientist to now choose between species. It has been
determined there is a high evolutionary divergence between mice and rats with their
most common ancestor existing roughly 20 million years ago, according to the
molecular clock technique (Kumar and Hedges 1998; Huchon, Catzeflis and Douzery
2000). There are differential expression of genes when examining the most commonly
used mouse and rat lines, C57BL/6 mice and Sprague Dawley rats. Out of 10,833
genes, 4,713 were differentially expressed in hippocampal neuronal dendrites (Francis
et al. 2014). This is an important fact due to the critical importance of the hippocampus
in learning and memory, and understanding species differences in many cognitive tests.
Within AS, there are many advantages to using a rat model over a mouse model.
Rats, in general, have a much larger brain and body size facilitating the utilization of a
wider array of cognitive, social, and biochemical techniques allowing us to better
understand the AS condition. Rats have superior maze-learning skills demonstrating a
higher level of strategy with a more stable performance in lengthy cognitive trials
(Whishaw and Tomie 1996). Mice tend to take much longer to learn tasks such as water
maze when compared to rats. There is also a significant difference in neurogenesis
within the hippocampus (Snyder et al. 2009). Neurogenesis is not only significantly
larger in rats, the new neurons mature about two weeks earlier and are ten times more
likely to be activated during learning and memory as well as twice as likely to escape
cell death. This demonstrates a major difference in neuronal plasticity which was not
limited to the hippocampus, extending to the cortical regions. One major technique that
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is advantageous in the rat, and will be mentioned within chapter 4, is microdialysis. Due
to the larger brain size, the surgery is not only easier, but the cannula insertion will
cause less damage to a smaller area of the brain. We will also be able to collect much
more sample at shorter time periods increasing the sensitivity of the technique. Within
the pharmaceutical industry it has become standardized to use the rat for a
physiological and toxicological model (Parasuraman 2011). This made the creation and
characterization of an AS rat model essential for accurate assessment of future
therapeutics.
Rats overall are less stressed by human contact making them much easier to
handle (Meijer et al. 2007; Ellenbroek and Youn 2016). A major advantage is they can
also be trained to remain still for certain procedures eliminating the need for anesthesia.
There are also physiological differences in the way rats and mice handle serotonin and
dopamine delivery meaning they behave differently in impulsivity, habit formation, and
other situations related to addiction and some psychiatric disorders. There is a
significant differences in serotonin receptor distribution between these two species.
Within the dorsal and ventral striatum rats demonstrate very high levels of 5-HT6 mRNA
with more receptor binding, being more similar to humans than mice (Hirst et al. 2003).
Changes in serotonin functioning have been implicated in anxiety disorders, autism
spectrum disorder, as well as many others (Gabriele, Sacco and Persico 2014; Corchs
et al. 2015). Rats, like humans, have pharmacological differences compared to mice
due to a change in a 5-HT6 receptor binding pocket. Antagonists to 5-HT6 receptors
have a high binding affinity in humans and rats, and a much lower affinity for mouse 5HT6 receptors. The receptor distribution differences are also thought to be the reason
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behind rats demonstrating more impulsive behavior while mice are more able to handle
premature responses. Reports have also demonstrated mice and rats react very
differently to exposure of nicotine, alcohol, and MDMA.
Another important aspect to mention when considering mice versus rats, is the
difference in social behavior. Rats are much less aggressive than mice and are more
social in comparison mimicking the human more closely than mice ( Blanchard et al.
2001; Lore and Flannelly 1977). In the context of disorders such as AS, which have
been correlated to autism spectrum disorder (ASD), rats are a more appropriate species
to assess social behavior.
Although inbred strains offer genetic uniformity, the outbred stocks, known for
genetic variability are often used to potentially more closely mimic what one would find
in the human population. We used the outbred Sprague–Dawley rats to represent more
diversity and thus potentially provide more translatability to the human AS population.
As discussed above, there are many advantages to using a rat model over a mouse
model to mimic a human disorder, including its genetic similarity (90% of rat genes
possess strict orthologues of the human genes (Gibbs et al. 2004) and its closer
resemblance to human physiology. The rat has a much higher level of complexity within
its physiological systems, more accurately reflecting human physiology than mice
(Iannaccone and Jacob 2009). Another example of this is Melatonin, an important
mediator for complex physiological functions including circadian regulation, sleep, and
cognition (which are all disrupted in AS). Most inbred mouse strains, including,
C57BL/6, have been reported to be deficient in melatonin, while rats similar to humans
produce this hormone (Ebihara et al. 1986; Roseboom et al. 1998; Stehle, von Gall and
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Korf 2002; Korf, Von Gall and Stehle 2003) This can make the rat a much more relevant
model for neuropsychiatric disorders.

1.11 Reference

Adelman, John P., Maylie, James and Sah, Pankaj. 2012. Small-Conductance Ca2+Activated K+ Channels: Form and Function. Annual Review of Physiology 74(1):
245-69.
Aldenkamp, A. and Arends, J. 2004. The relative influence of epileptic EEG discharges,
short nonconvulsive seizures, and type of epilepsy on cognitive function.
Epilepsia 45(1): 54-63.
Angelman, Harry. 1965. ‘Puppet’ Children A Report on Three Cases. Developmental
Medicine & Child Neurology 7(6): 681-88.
Avagliano Trezza, R., Sonzogni, M., Bossuyt, S. N. V., Zampeta, F. I., Punt, A. M., van
den Berg, M., Rotaru, D. C., Koene, L. M. C., Munshi, S. T., Stedehouder, J.,
Kros, J. M., Williams, M., Heussler, H., de Vrij, F. M. S., Mientjes, E. J., van
Woerden, G. M., Kushner, S. A., Distel, B. and Elgersma, Y. 2019. Loss of
nuclear UBE3A causes electrophysiological and behavioral deficits in mice and is
associated with Angelman syndrome. Nat Neurosci 22(8): 1235-47.
Bach, Mary Elizabeth, Hawkins, Robert D., Osman, Mona, Kandel, Eric R. and Mayford,
Mark. 1995. Impairment of spatial but not contextual memory in CaMKII mutant
mice with a selective loss of hippocampal ltp in the range of the θ frequency. Cell
81(6): 905-15.

26

Bhat, K. P., Yan, S., Wang, C. E., Li, S. and Li, X. J. 2014. Differential ubiquitination and
degradation of huntingtin fragments modulated by ubiquitin-protein ligase E3A.
Proc Natl Acad Sci U S A 111(15): 5706-11.
Blanchard, R. J., Dulloog, L., Markham, C., Nishimura, O., Nikulina Compton, J., Jun,
A., Han, C. and Blanchard, D. C. 2001. Sexual and aggressive interactions in a
visible burrow system with provisioned burrows. Physiol Behav 72(1-2): 245-54.
Born, H. A., Dao, A. T., Levine, A. T., Lee, W. L., Mehta, N. M., Mehra, S., Weeber, E.
J. and Anderson, A. E. 2017. Strain-dependence of the Angelman Syndrome
phenotypes in Ube3a maternal deficiency mice. Sci Rep 7(1): 8451.
Boyd, S. G., Harden, A. and Patton, M. A. 1988. The EEG in early diagnosis of the
Angelman (happy puppet) syndrome. Eur J Pediatr 147(5): 508-13.
Bruinsma, C. F., Schonewille, M., Gao, Z., Aronica, E. M., Judson, M. C., Philpot, B. D.,
Hoebeek, F. E., van Woerden, G. M., De Zeeuw, C. I. and Elgersma, Y. 2015.
Dissociation of locomotor and cerebellar deficits in a murine Angelman syndrome
model. J Clin Invest 125(11): 4305-15.
Cao, C., Rioult-Pedotti, M. S., Migani, P., Yu, C. J., Tiwari, R., Parang, K., Spaller, M.
R., Goebel, D. J. and Marshall, J. 2013. Impairment of TrkB-PSD-95 signaling in
Angelman syndrome. PLoS Biol 11(2): e1001478.
Cassidy, Suzanne B., Schwartz, Stuart, Miller, Jennifer L. and Driscoll, Daniel J. 2012.
Prader-Willi syndrome. Genetics in Medicine 14(1): 10-26.
Cheron, G., Servais, L., Wagstaff, J. and Dan, B. 2005. Fast cerebellar oscillation
associated with ataxia in a mouse model of Angelman syndrome. Neuroscience
130(3): 631-7.

27

Ciechanover, A., Heller, H., Katz-Etzion, R. and Hershko, A. 1981. Activation of the
heat-stable polypeptide of the ATP-dependent proteolytic system. Proc Natl Acad
Sci U S A 78(2): 761-5.
Clayton-Smith, J. 1993. Clinical research on Angelman syndrome in the United
Kingdom: observations on 82 affected individuals. Am J Med Genet 46(1): 12-5.
Clayton-Smith, J. and Laan, L. 2003. Angelman syndrome: a review of the clinical and
genetic aspects. J Med Genet 40(2): 87-95.
Clayton-Smith, J. and Pembrey, M. E. 1992. Angelman syndrome. J Med Genet 29(6):
412-5.
Colas, D., Wagstaff, J., Fort, P., Salvert, D. and Sarda, N. 2005. Sleep disturbances in
Ube3a maternal-deficient mice modeling Angelman syndrome. Neurobiol Dis
20(2): 471-8.
Copping, N. A., Christian, S. G. B., Ritter, D. J., Islam, M. S., Buscher, N., Zolkowska,
D., Pride, M. C., Berg, E. L., LaSalle, J. M., Ellegood, J., Lerch, J. P., Reiter, L.
T., Silverman, J. L. and Dindot, S. V. 2017. Neuronal overexpression of Ube3a
isoform 2 causes behavioral impairments and neuroanatomical pathology
relevant to 15q11.2-q13.3 duplication syndrome. Hum Mol Genet 26(20): 39954010.
Corchs, F., Nutt, D. J., Hince, D. A., Davies, S. J., Bernik, M. and Hood, S. D. 2015.
Evidence for serotonin function as a neurochemical difference between fear and
anxiety disorders in humans? J Psychopharmacol 29(10): 1061-9.
Crawley, J. N., Belknap, J. K., Collins, A., Crabbe, J. C., Frankel, W., Henderson, N.,
Hitzemann, R. J., Maxson, S. C., Miner, L. L., Silva, A. J., Wehner, J. M.,

28

Wynshaw-Boris, A. and Paylor, R. 1997. Behavioral phenotypes of inbred mouse
strains: implications and recommendations for molecular studies.
Psychopharmacology (Berl) 132(2): 107-24.
den Bakker, H., Sidorov, M. S., Fan, Z., Lee, D. J., Bird, L. M., Chu, C. J. and Philpot, B.
D. 2018. Abnormal coherence and sleep composition in children with Angelman
syndrome: a retrospective EEG study. Mol Autism 9: 32.
Didden, R., Korzilius, H., Smits, M. G. and Curfs, L. M. 2004. Sleep problems in
individuals with Angelman syndrome. Am J Ment Retard 109(4): 275-84.
Dindot, S. V., Antalffy, B. A., Bhattacharjee, M. B. and Beaudet, A. L. 2008. The
Angelman syndrome ubiquitin ligase localizes to the synapse and nucleus, and
maternal deficiency results in abnormal dendritic spine morphology. Hum Mol
Genet 17(1): 111-8.
Ebihara, S., Marks, T., Hudson, D. J. and Menaker, M. 1986. Genetic control of
melatonin synthesis in the pineal gland of the mouse. Science 231(4737): 491-3.
Egawa, K., Kitagawa, K., Inoue, K., Takayama, M., Takayama, C., Saitoh, S., Kishino,
T., Kitagawa, M. and Fukuda, A. 2012. Decreased tonic inhibition in cerebellar
granule cells causes motor dysfunction in a mouse model of Angelman
syndrome. Sci Transl Med 4(163): 163ra57.
Ehlen, J. C., Jones, K. A., Pinckney, L., Gray, C. L., Burette, S., Weinberg, R. J., Evans,
J. A., Brager, A. J., Zylka, M. J., Paul, K. N., Philpot, B. D. and DeBruyne, J. P.
2015. Maternal Ube3a Loss Disrupts Sleep Homeostasis But Leaves Circadian
Rhythmicity Largely Intact. J Neurosci 35(40): 13587-98.

29

El Hokayem, J., Weeber, E. and Nawaz, Z. 2018. Loss of Angelman Syndrome Protein
E6AP Disrupts a Novel Antagonistic Estrogen-Retinoic Acid Transcriptional
Crosstalk in Neurons. Mol Neurobiol 55(9): 7187-200.
Ellenbroek, B. and Youn, J. 2016. Rodent models in neuroscience research: is it a rat
race? Dis Model Mech 9(10): 1079-87.
Filonova, I., Trotter, J. H., Banko, J. L. and Weeber, E. J. 2014. Activity-dependent
changes in MAPK activation in the Angelman Syndrome mouse model. Learn
Mem 21(2): 98-104.
Fog, J. U., Khoshbouei, H., Holy, M., Owens, W. A., Vaegter, C. B., Sen, N.,
Nikandrova, Y., Bowton, E., McMahon, D. G., Colbran, R. J., Daws, L. C., Sitte,
H. H., Javitch, J. A., Galli, A. and Gether, U. 2006. Calmodulin kinase II interacts
with the dopamine transporter C terminus to regulate amphetamine-induced
reverse transport. Neuron 51(4): 417-29.
Francis, C., Natarajan, S., Lee, M. T., Khaladkar, M., Buckley, P. T., Sul, J. Y.,
Eberwine, J. and Kim, J. 2014. Divergence of RNA localization between rat and
mouse neurons reveals the potential for rapid brain evolution. BMC Genomics
15(1): 883.
Gabriele, S., Sacco, R. and Persico, A. M. 2014. Blood serotonin levels in autism
spectrum disorder: a systematic review and meta-analysis. Eur
Neuropsychopharmacol 24(6): 919-29.
George, Arlene J., Hoffiz, Yarely C., Charles, Antoinette J., Zhu, Ying and Mabb, Angela
M. 2018. A Comprehensive Atlas of E3 Ubiquitin Ligase Mutations in
Neurological Disorders. Frontiers in Genetics 9(29).

30

Gibbs, R. A., Weinstock, G. M., Metzker, M. L., Muzny, D. M., Sodergren, E. J.,
Scherer, S., Scott, G., Steffen, D., Worley, K. C., Burch, P. E., Okwuonu, G.,
Hines, S., Lewis, L., DeRamo, C., Delgado, O., Dugan-Rocha, S., Miner, G.,
Morgan, M., Hawes, A., Gill, R., Celera, Holt, R. A., Adams, M. D., Amanatides,
P. G., Baden-Tillson, H., Barnstead, M., Chin, S., Evans, C. A., Ferriera, S.,
Fosler, C., Glodek, A., Gu, Z., Jennings, D., Kraft, C. L., Nguyen, T., Pfannkoch,
C. M., Sitter, C., Sutton, G. G., Venter, J. C., Woodage, T., Smith, D., Lee, H. M.,
Gustafson, E., Cahill, P., Kana, A., Doucette-Stamm, L., Weinstock, K., Fechtel,
K., Weiss, R. B., Dunn, D. M., Green, E. D., Blakesley, R. W., Bouffard, G. G.,
De Jong, P. J., Osoegawa, K., Zhu, B., Marra, M., Schein, J., Bosdet, I., Fjell, C.,
Jones, S., Krzywinski, M., Mathewson, C., Siddiqui, A., Wye, N., McPherson, J.,
Zhao, S., Fraser, C. M., Shetty, J., Shatsman, S., Geer, K., Chen, Y., Abramzon,
S., Nierman, W. C., Havlak, P. H., Chen, R., Durbin, K. J., Egan, A., Ren, Y.,
Song, X. Z., Li, B., Liu, Y., Qin, X., Cawley, S., Worley, K. C., Cooney, A. J.,
D'Souza, L. M., Martin, K., Wu, J. Q., Gonzalez-Garay, M. L., Jackson, A. R.,
Kalafus, K. J., McLeod, M. P., Milosavljevic, A., Virk, D., Volkov, A., Wheeler, D.
A., Zhang, Z., Bailey, J. A., Eichler, E. E., Tuzun, E., Birney, E., Mongin, E.,
Ureta-Vidal, A., Woodwark, C., Zdobnov, E., Bork, P., Suyama, M., Torrents, D.,
Alexandersson, M., Trask, B. J., Young, J. M., Huang, H., Wang, H., Xing, H.,
Daniels, S., Gietzen, D., Schmidt, J., Stevens, K., Vitt, U., Wingrove, J., Camara,
F., Mar Albà, M., Abril, J. F., Guigo, R., Smit, A., Dubchak, I., Rubin, E. M.,
Couronne, O., Poliakov, A., Hübner, N., Ganten, D., Goesele, C., Hummel, O.,
Kreitler, T., Lee, Y. A., Monti, J., Schulz, H., Zimdahl, H., Himmelbauer, H.,

31

Lehrach, H., Jacob, H. J., Bromberg, S., Gullings-Handley, J., Jensen-Seaman,
M. I., Kwitek, A. E., Lazar, J., Pasko, D., Tonellato, P. J., Twigger, S., Ponting, C.
P., Duarte, J. M., Rice, S., Goodstadt, L., Beatson, S. A., Emes, R. D., Winter, E.
E., Webber, C., Brandt, P., Nyakatura, G., Adetobi, M., Chiaromonte, F., Elnitski,
L., Eswara, P., Hardison, R. C., Hou, M., Kolbe, D., Makova, K., Miller, W.,
Nekrutenko, A., Riemer, C., Schwartz, S., Taylor, J., Yang, S., Zhang, Y.,
Lindpaintner, K., Andrews, T. D., Caccamo, M., Clamp, M., Clarke, L., Curwen,
V., Durbin, R., Eyras, E., Searle, S. M., Cooper, G. M., Batzoglou, S., Brudno,
M., Sidow, A., Stone, E. A., Venter, J. C., Payseur, B. A., Bourque, G., LópezOtín, C., Puente, X. S., Chakrabarti, K., Chatterji, S., Dewey, C., Pachter, L.,
Bray, N., Yap, V. B., Caspi, A., Tesler, G., Pevzner, P. A., Haussler, D., Roskin,
K. M., Baertsch, R., Clawson, H., Furey, T. S., Hinrichs, A. S., Karolchik, D.,
Kent, W. J., Rosenbloom, K. R., Trumbower, H., Weirauch, M., Cooper, D. N.,
Stenson, P. D., Ma, B., Brent, M., Arumugam, M., Shteynberg, D., Copley, R. R.,
Taylor, M. S., Riethman, H., Mudunuri, U., Peterson, J., Guyer, M., Felsenfeld,
A., Old, S., Mockrin, S. and Collins, F. 2004. Genome sequence of the Brown
Norway rat yields insights into mammalian evolution. Nature 428(6982): 493-521.
Giroud, M., Daubail, B., Khayat, N., Chouchane, M., Berger, E., Muzard, E., Medeiros
de Bustos, E., Thauvin-Robinet, C., Faivre, L., Masurel, A., Darmency-Stamboul,
V., Huet, F., Béjot, Y., Giroud, M. and Moulin, T. 2015. Angelman syndrome: a
case series assessing neurological issues in adulthood. Eur Neurol 73(1-2): 11925.

32

Greer, P. L., Hanayama, R., Bloodgood, B. L., Mardinly, A. R., Lipton, D. M., Flavell, S.
W., Kim, T. K., Griffith, E. C., Waldon, Z., Maehr, R., Ploegh, H. L., Chowdhury,
S., Worley, P. F., Steen, J. and Greenberg, M. E. 2010. The Angelman
Syndrome protein Ube3A regulates synapse development by ubiquitinating arc.
Cell 140(5): 704-16.
Haas, A. L. and Rose, I. A. 1982. The mechanism of ubiquitin activating enzyme. A
kinetic and equilibrium analysis. J Biol Chem 257(17): 10329-37.
Hallengren, J. J. and Vaden, R. J. 2014. Sodium-potassium ATPase emerges as a
player in hippocampal phenotypes of Angelman syndrome mice. J Neurophysiol
112(1): 5-8.
Heck, D. H., Zhao, Y., Roy, S., LeDoux, M. S. and Reiter, L. T. 2008. Analysis of
cerebellar function in Ube3a-deficient mice reveals novel genotype-specific
behaviors. Hum Mol Genet 17(14): 2181-9.
Helmstaedter, C., Kurthen, M., Lux, S., Reuber, M. and Elger, C. E. 2003. Chronic
epilepsy and cognition: a longitudinal study in temporal lobe epilepsy. Ann Neurol
54(4): 425-32.
Hermann, B., Seidenberg, M., Bell, B., Rutecki, P., Sheth, R., Ruggles, K., Wendt, G.,
O'Leary, D. and Magnotta, V. 2002. The neurodevelopmental impact of
childhood-onset temporal lobe epilepsy on brain structure and function. Epilepsia
43(9): 1062-71.
Hershko, A., Ciechanover, A. and Rose, I. A. 1979. Resolution of the ATP-dependent
proteolytic system from reticulocytes: a component that interacts with ATP. Proc
Natl Acad Sci U S A 76(7): 3107-10.

33

Hershko, A., Ciechanover, A. and Rose, I. A. 1981. Identification of the active amino
acid residue of the polypeptide of ATP-dependent protein breakdown. J Biol
Chem 256(4): 1525-8.
Hershko, A., Heller, H., Elias, S. and Ciechanover, A. 1983. Components of ubiquitinprotein ligase system. Resolution, affinity purification, and role in protein
breakdown. J Biol Chem 258(13): 8206-14.
Hirst, W. D., Abrahamsen, B., Blaney, F. E., Calver, A. R., Aloj, L., Price, G. W. and
Medhurst, A. D. 2003. Differences in the central nervous system distribution and
pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat
and human receptors investigated by radioligand binding, site-directed
mutagenesis, and molecular modeling. Mol Pharmacol 64(6): 1295-308.
HS, Huang, AJ, Burns, RJ, Nonneman, LK, Baker, NV, Riddick, VD, Nikolova, TT,
Riday, K, Yashiro, BD, Philpot and SS, Moy. 2013. Behavioral deficits in
an Angelman syndrome model : effects of genetic background and age .
Behavioural Brain Research 243(15): 79-90.
Huang, H. S., Burns, A. J., Nonneman, R. J., Baker, L. K., Riddick, N. V., Nikolova, V.
D., Riday, T. T., Yashiro, K., Philpot, B. D. and Moy, S. S. 2013. Behavioral
deficits in an Angelman syndrome model: effects of genetic background and age.
Behav Brain Res 243: 79-90.
Huchon, D., Catzeflis, F. M. and Douzery, E. J. 2000. Variance of molecular datings,
evolution of rodents and the phylogenetic affinities between Ctenodactylidae and
Hystricognathi. Proc Biol Sci 267(1441): 393-402.
Iannaccone, P. M. and Jacob, H. J. 2009. Rats! Dis Model Mech 2(5-6): 206-10.

34

Ikeda, F. and Dikic, I. 2008. Atypical ubiquitin chains: new molecular signals. 'Protein
Modifications: Beyond the Usual Suspects' review series. EMBO Rep 9(6): 53642.
Jay, Venita, Becker, Laurence E., Chan, F-W. and Perry, Thomas L. 1991. Puppet‐like
syndrome of Angelman. A pathologic and neurochemical study 41(3): 416-16.
Jiang, Y. H., Armstrong, D., Albrecht, U., Atkins, C. M., Noebels, J. L., Eichele, G.,
Sweatt, J. D. and Beaudet, A. L. 1998. Mutation of the Angelman ubiquitin ligase
in mice causes increased cytoplasmic p53 and deficits of contextual learning and
long-term potentiation. Neuron 21(4): 799-811.
Jiang, Y. H., Pan, Y., Zhu, L., Landa, L., Yoo, J., Spencer, C., Lorenzo, I., Brilliant, M.,
Noebels, J. and Beaudet, A. L. 2010. Altered ultrasonic vocalization and impaired
learning and memory in Angelman syndrome mouse model with a large maternal
deletion from Ube3a to Gabrb3. PLoS One 5(8): e12278.
Judson, M. C., Sosa-Pagan, J. O., Del Cid, W. A., Han, J. E. and Philpot, B. D. 2014.
Allelic specificity of Ube3a expression in the mouse brain during postnatal
development. J Comp Neurol 522(8): 1874-96.
Kao, W. H., Beaudenon, S. L., Talis, A. L., Huibregtse, J. M. and Howley, P. M. 2000.
Human papillomavirus type 16 E6 induces self-ubiquitination of the E6AP
ubiquitin-protein ligase. J Virol 74(14): 6408-17.
Kaphzan, H., Buffington, S. A., Ramaraj, A. B., Lingrel, J. B., Rasband, M. N., Santini,
E. and Klann, E. 2013. Genetic reduction of the α1 subunit of Na/K-ATPase
corrects multiple hippocampal phenotypes in Angelman syndrome. Cell Rep 4(3):
405-12.

35

Kaphzan, H., Hernandez, P., Jung, J. I., Cowansage, K. K., Deinhardt, K., Chao,
M. V., Abel, T. and Klann, E. 2012. Reversal of impaired hippocampal
long-term potentiation and contextual fear memory deficits in Angelman
syndrome model mice by ErbB inhibitors. Biol Psychiatry 72(3): 182-90.
Kim, H. T., Kim, K. P., Lledias, F., Kisselev, A. F., Scaglione, K. M., Skowyra, D., Gygi,
S. P. and Goldberg, A. L. 2007. Certain pairs of ubiquitin-conjugating enzymes
(E2s) and ubiquitin-protein ligases (E3s) synthesize nondegradable forked
ubiquitin chains containing all possible isopeptide linkages. J Biol Chem 282(24):
17375-86.
Kishino, T., Lalande, M. and Wagstaff, J. 1997. UBE3A/E6-AP mutations cause
Angelman syndrome. Nat Genet 15(1): 70-3.
Korf, H. W., Von Gall, C. and Stehle, J. 2003. The circadian system and melatonin:
lessons from rats and mice. Chronobiol Int 20(4): 697-710.
Kumar, S. and Hedges, S. B. 1998. A molecular timescale for vertebrate evolution.
Nature 392(6679): 917-20.
Laan, L. A. and Vein, A. A. 2005. Angelman syndrome: is there a characteristic EEG?
Brain Dev 27(2): 80-7.
Larson, A. M., Shinnick, J. E., Shaaya, E. A., Thiele, E. A. and Thibert, R. L. 2015.
Angelman syndrome in adulthood. Am J Med Genet A 167a(2): 331-44.
Li, W. and Ye, Y. 2008. Polyubiquitin chains: functions, structures, and mechanisms.
Cell Mol Life Sci 65(15): 2397-406.

36

Liu, X. Y., Mao, L. M., Zhang, G. C., Papasian, C. J., Fibuch, E. E., Lan, H. X., Zhou, H.
F., Xu, M. and Wang, J. Q. 2009. Activity-dependent modulation of limbic
dopamine D3 receptors by CaMKII. Neuron 61(3): 425-38.
Liu, Yan, Johe, Karl, Sun, Jiandong, Hao, Xiaoning, Wang, Yubin, Bi, Xiaoning and
Baudry, Michel. 2019. Enhancement of synaptic plasticity and reversal of
impairments in motor and cognitive functions in a mouse model of Angelman
Syndrome by a small neurogenic molecule, NSI-189. Neuropharmacology 144:
337-44.
Llewellyn, K. J., Nalbandian, A., Gomez, A., Wei, D., Walker, N. and Kimonis, V. E.
2015. Administration of CoQ10 analogue ameliorates dysfunction of the
mitochondrial respiratory chain in a mouse model of Angelman syndrome.
Neurobiol Dis 76: 77-86.
Lore, R. and Flannelly, K. 1977. Rat societies. Sci Am 236(5): 106-11, 13-6.
Magenis, R. E., Brown, M. G., Lacy, D. A., Budden, S. and LaFranchi, S. 1987. Is
Angelman syndrome an alternate result of del(15)(q11q13)? Am J Med Genet
28(4): 829-38.
Man, H. Y., Wang, Q., Lu, W. Y., Ju, W., Ahmadian, G., Liu, L., D'Souza, S., Wong, T.
P., Taghibiglou, C., Lu, J., Becker, L. E., Pei, L., Liu, F., Wymann, M. P.,
MacDonald, J. F. and Wang, Y. T. 2003. Activation of PI3-kinase is required for
AMPA receptor insertion during LTP of mEPSCs in cultured hippocampal
neurons. Neuron 38(4): 611-24.
Mandel-Brehm, Caleigh, Salogiannis, John, Dhamne, Sameer C., Rotenberg, Alexander
and Greenberg, Michael E. 2015. Seizure-like activity in a juvenile Angelman

37

syndrome mouse model is attenuated by reducing <em>Arc</em> expression.
Proceedings of the National Academy of Sciences 112(16): 5129-34.
Mardirossian, S., Rampon, C., Salvert, D., Fort, P. and Sarda, N. 2009. Impaired
hippocampal plasticity and altered neurogenesis in adult Ube3a maternal
deficient mouse model for Angelman syndrome. Exp Neurol 220(2): 341-8.
Margolis, S. S., Salogiannis, J., Lipton, D. M., Mandel-Brehm, C., Wills, Z. P., Mardinly,
A. R., Hu, L., Greer, P. L., Bikoff, J. B., Ho, H. Y., Soskis, M. J., Sahin, M. and
Greenberg, M. E. 2010. EphB-mediated degradation of the RhoA GEF Ephexin5
relieves a developmental brake on excitatory synapse formation. Cell 143(3):
442-55.
Matsuura, T., Sutcliffe, J. S., Fang, P., Galjaard, R. J., Jiang, Y. H., Benton, C. S.,
Rommens, J. M. and Beaudet, A. L. 1997. De novo truncating mutations in E6AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome. Nat Genet
15(1): 74-7.
Meijer, M. K., Sommer, R., Spruijt, B. M., van Zutphen, L. F. and Baumans, V. 2007.
Influence of environmental enrichment and handling on the acute stress
response in individually housed mice. Lab Anim 41(2): 161-73.
Meng, L., Person, R. E. and Beaudet, A. L. 2012. Ube3a-ATS is an atypical RNA
polymerase II transcript that represses the paternal expression of Ube3a. Hum
Mol Genet 21(13): 3001-12.
Meng, L., Person, R. E., Huang, W., Zhu, P. J., Costa-Mattioli, M. and Beaudet, A. L.
2013. Truncation of Ube3a-ATS unsilences paternal Ube3a and ameliorates

38

behavioral defects in the Angelman syndrome mouse model. PLoS Genet 9(12):
e1004039.
Meng, Linyan, Ward, Amanda J., Chun, Seung, Bennett, C. Frank, Beaudet, Arthur L.
and Rigo, Frank. 2015. Towards a therapy for Angelman syndrome by targeting a
long non-coding RNA. Nature 518(7539): 409-12.
Miano, Silvia, Bruni, Oliviero, Leuzzi, Vincenzo, Elia, Maurizio, Verrillo, Elisabetta and
Ferri, Raffaele. 2004. Sleep polygraphy in Angelman syndrome. Clinical
Neurophysiology 115(4): 938-45.
Minassian, B. A., DeLorey, T. M., Olsen, R. W., Philippart, M., Bronstein, Y., Zhang, Q.,
Guerrini, R., Van Ness, P., Livet, M. O. and Delgado-Escueta, A. V. 1998.
Angelman syndrome: correlations between epilepsy phenotypes and genotypes.
Ann Neurol 43(4): 485-93.
Moncla, Anne, Malzac, Perrine, Voelckel, Marie-Antoinette, Auquier, Pascal, Girardot,
Lydie, Mattei, Marie-Genevieve, Philip, Nicole, Mattei, Jean-François, Lalande,
Marc and Livet, Marie-Odile. 1999. Phenotype–genotype correlation in 20
deletion and 20 non-deletion Angelman syndrome patients. European Journal of
Human Genetics 7(2): 131-39.
Ohtsuki, Gen, Piochon, Claire, Adelman, John P and Hansel, Christian. 2012. SK2
Channel Modulation Contributes to Compartment-Specific Dendritic Plasticity in
Cerebellar Purkinje Cells. Neuron 75(1): 108-20.
Olabarria, Markel, Pasini, Silvia, Corona, Carlo, Robador, Pablo, Song, Cheng, Patel,
Hardik and Lefort, Roger. 2019. Dysfunction of the ubiquitin ligase E3A

39

Ube3A/E6-AP contributes to synaptic pathology in Alzheimer’s disease.
Communications Biology 2(1): 111.
Padmanabhan, S., Lambert, N. A. and Prasad, B. M. 2008. Activity-dependent
regulation of the dopamine transporter is mediated by Ca(2+)/calmodulindependent protein kinase signaling. Eur J Neurosci 28(10): 2017-27.
Parasuraman, S. 2011. Toxicological screening. J Pharmacol Pharmacother 2(2): 74-9.
Pelc, K., Cheron, G. and Dan, B. 2008. Behavior and neuropsychiatric manifestations in
Angelman syndrome. Neuropsychiatr Dis Treat 4(3): 577-84.
Peters, S. U., Kaufmann, W. E., Bacino, C. A., Anderson, A. W., Adapa, P., Chu, Z.,
Yallampalli, R., Traipe, E., Hunter, J. V. and Wilde, E. A. 2011. Alterations in
white matter pathways in Angelman syndrome. Dev Med Child Neurol 53(4): 3617.
Prasad, A., Grocott, O., Parkin, K., Larson, A. and Thibert, R. L. 2018. Angelman
syndrome in adolescence and adulthood: A retrospective chart review of 53
cases. Am J Med Genet A 176(6): 1327-34.
Ramamoorthy, S. and Nawaz, Z. 2008. E6-associated protein (E6-AP) is a dual function
coactivator of steroid hormone receptors. Nucl Recept Signal 6: e006.
Riday, T. T., Dankoski, E. C., Krouse, M. C., Fish, E. W., Walsh, P. L., Han, J. E.,
Hodge, C. W., Wightman, R. M., Philpot, B. D. and Malanga, C. J. 2012.
Pathway-specific dopaminergic deficits in a mouse model of Angelman
syndrome. J Clin Invest 122(12): 4544-54.
Roseboom, P. H., Namboodiri, M. A., Zimonjic, D. B., Popescu, N. C., Rodriguez, I. R.,
Gastel, J. A. and Klein, D. C. 1998. Natural melatonin 'knockdown' in C57BL/6J

40

mice: rare mechanism truncates serotonin N-acetyltransferase. Brain Res Mol
Brain Res 63(1): 189-97.
Salminen, I., Read, S., Hurd, P. and Crespi, B. 2019. Genetic variation of UBE3A is
associated with schizotypy in a population of typical individuals. Psychiatry Res
275: 94-99.
Santini, E., Turner, K. L., Ramaraj, A. B., Murphy, M. P., Klann, E. and Kaphzan, H.
2015. Mitochondrial Superoxide Contributes to Hippocampal Synaptic
Dysfunction and Memory Deficits in Angelman Syndrome Model Mice. J Neurosci
35(49): 16213-20.
Sato, Masaaki and Stryker, Michael P. 2010. Genomic imprinting of experiencedependent cortical plasticity by the ubiquitin ligase gene <em>Ube3a</em>.
Proceedings of the National Academy of Sciences 107(12): 5611-16.
Scheffner, M., Nuber, U. and Huibregtse, J. M. 1995. Protein ubiquitination involving an
E1-E2-E3 enzyme ubiquitin thioester cascade. Nature 373(6509): 81-3.
Shi, S. Q., Bichell, T. J., Ihrie, R. A. and Johnson, C. H. 2015. Ube3a imprinting impairs
circadian robustness in Angelman syndrome models. Curr Biol 25(5): 537-45.
Sidorov, Michael S., Judson, Matthew C., Kim, Hyojin, Rougie, Marie, Ferrer, Alejandra
I., Nikolova, Viktoriya D., Riddick, Natallia V., Moy, Sheryl S. and Philpot,
Benjamin D. 2018. Enhanced Operant Extinction and Prefrontal Excitability in a
Mouse Model of Angelman Syndrome. The Journal of Neuroscience 38(11):
2671-82.

41

Singhmar, P. and Kumar, A. 2011. Angelman syndrome protein UBE3A interacts with
primary microcephaly protein ASPM, localizes to centrosomes and regulates
chromosome segregation. PLoS One 6(5): e20397.
Snyder, J. S., Choe, J. S., Clifford, M. A., Jeurling, S. I., Hurley, P., Brown, A., Kamhi, J.
F. and Cameron, H. A. 2009. Adult-born hippocampal neurons are more
numerous, faster maturing, and more involved in behavior in rats than in mice. J
Neurosci 29(46): 14484-95.
Stehle, J. H., von Gall, C. and Korf, H. W. 2002. Organisation of the circadian system in
melatonin-proficient C3H and melatonin-deficient C57BL mice: a comparative
investigation. Cell Tissue Res 309(1): 173-82.
Su, H., Fan, W., Coskun, P. E., Vesa, J., Gold, J. A., Jiang, Y. H., Potluri, P., Procaccio,
V., Acab, A., Weiss, J. H., Wallace, D. C. and Kimonis, V. E. 2011. Mitochondrial
dysfunction in CA1 hippocampal neurons of the UBE3A deficient mouse model
for Angelman syndrome. Neurosci Lett 487(2): 129-33.
Sui, L., Wang, J. and Li, B. M. 2008. Role of the phosphoinositide 3-kinase-Aktmammalian target of the rapamycin signaling pathway in long-term potentiation
and trace fear conditioning memory in rat medial prefrontal cortex. Learn Mem
15(10): 762-76.
Sun, J., Liu, Y., Tran, J., O'Neal, P., Baudry, M. and Bi, X. 2016. mTORC1-S6K1
inhibition or mTORC2 activation improves hippocampal synaptic plasticity and
learning in Angelman syndrome mice. Cell Mol Life Sci 73(22): 4303-14.
Sun, J., Zhu, G., Liu, Y., Standley, S., Ji, A., Tunuguntla, R., Wang, Y., Claus, C., Luo,
Y., Baudry, M. and Bi, X. 2015. UBE3A Regulates Synaptic Plasticity and

42

Learning and Memory by Controlling SK2 Channel Endocytosis. Cell Rep 12(3):
449-61.
Sutula, T., Lauersdorf, S., Lynch, M., Jurgella, C. and Woodard, A. 1995. Deficits in
radial arm maze performance in kindled rats: evidence for long-lasting memory
dysfunction induced by repeated brief seizures. J Neurosci 15(12): 8295-301.
Thibert, R. L., Conant, K. D., Braun, E. K., Bruno, P., Said, R. R., Nespeca, M. P. and
Thiele, E. A. 2009. Epilepsy in Angelman syndrome: a questionnaire-based
assessment of the natural history and current treatment options. Epilepsia
50(11): 2369-76.
Thibert, Ronald L., Larson, Anna M., Hsieh, David T., Raby, Annabel R. and Thiele,
Elizabeth A. 2013. Neurologic Manifestations of Angelman Syndrome. Pediatric
Neurology 48(4): 271-79.
Trent, R. J., Sheffield, L. J., Deng, Z. M., Kim, W. S., Nassif, N. T., Ryce, C., Woods, C.
G., Michaelis, R. C., Tarleton, J. and Smith, A. 1997. The elusive Angelman
syndrome critical region. J Med Genet 34(9): 714-8.
Valente, K. D., Koiffmann, C. P., Fridman, C., Varella, M., Kok, F., Andrade, J. Q.,
Grossmann, R. M. and Marques-Dias, M. J. 2006. Epilepsy in patients with
angelman syndrome caused by deletion of the chromosome 15q11-13. Arch
Neurol 63(1): 122-8.
van Woerden, G. M., Harris, K. D., Hojjati, M. R., Gustin, R. M., Qiu, S., de Avila Freire,
R., Jiang, Y. H., Elgersma, Y. and Weeber, E. J. 2007. Rescue of neurological
deficits in a mouse model for Angelman syndrome by reduction of alphaCaMKII
inhibitory phosphorylation. Nat Neurosci 10(3): 280-2.

43

Wallace, M. L., Burette, A. C., Weinberg, R. J. and Philpot, B. D. 2012. Maternal loss of
Ube3a produces an excitatory/inhibitory imbalance through neuron type-specific
synaptic defects. Neuron 74(5): 793-800.
Watanabe, D., Inokawa, H., Hashimoto, K., Suzuki, N., Kano, M., Shigemoto, R.,
Hirano, T., Toyama, K., Kaneko, S., Yokoi, M., Moriyoshi, K., Suzuki, M.,
Kobayashi, K., Nagatsu, T., Kreitman, R. J., Pastan, I. and Nakanishi, S. 1998.
Ablation of cerebellar Golgi cells disrupts synaptic integration involving GABA
inhibition and NMDA receptor activation in motor coordination. Cell 95(1): 17-27.
Wheeler, A. C., Sacco, P. and Cabo, R. 2017. Unmet clinical needs and burden in
Angelman syndrome: a review of the literature. Orphanet J Rare Dis 12(1): 164.
Whishaw, I. Q. and Tomie, J. 1996. Of mice and mazes: similarities between mice and
rats on dry land but not water mazes. Physiol Behav 60(5): 1191-7.
Williams, C. A., Beaudet, A. L., Clayton-Smith, J., Knoll, J. H., Kyllerman, M., Laan, L.
A., Magenis, R. E., Moncla, A., Schinzel, A. A., Summers, J. A. and Wagstaff, J.
2006. Angelman syndrome 2005: updated consensus for diagnostic criteria. Am
J Med Genet A 140(5): 413-8.
Williams, C. A., Driscoll, D. J. and Dagli, A. I. 2010. Clinical and genetic aspects of
Angelman syndrome. Genet Med 12(7): 385-95.
Yamamoto, Yoshiki, Huibregtse, Jon M. and Howley, Peter M. 1997. The HumanE6APGene (UBE3A) Encodes Three Potential Protein Isoforms Generated by
Differential Splicing. Genomics 41(2): 263-66.
Yamasaki, K., Joh, K., Ohta, T., Masuzaki, H., Ishimaru, T., Mukai, T., Niikawa, N.,
Ogawa, M., Wagstaff, J. and Kishino, T. 2003. Neurons but not glial cells show

44

reciprocal imprinting of sense and antisense transcripts of Ube3a. Human
Molecular Genetics 12(8): 837-47.
Yi, J. J., Berrios, J., Newbern, J. M., Snider, W. D., Philpot, B. D., Hahn, K. M. and
Zylka, M. J. 2015. An Autism-Linked Mutation Disables Phosphorylation Control
of UBE3A. Cell 162(4): 795-807.
Zaaroor-Regev, D., de Bie, P., Scheffner, M., Noy, T., Shemer, R., Heled, M., Stein, I.,
Pikarsky, E. and Ciechanover, A. 2010. Regulation of the polycomb protein
Ring1B by self-ubiquitination or by E6-AP may have implications to the
pathogenesis of Angelman syndrome. Proc Natl Acad Sci U S A 107(15): 678893.

45

CHAPTER TWO:
GENERATION OF A NOVEL RAT MODEL OF ANGELMAN SYNDROME WITH A
COMPLETE UBE3A GENE DELETION1

2.1 Abstract
Angelman syndrome (AS) is a rare genetic disorder characterized by severe
intellectual disability, seizures, lack of speech, and ataxia. The gene responsible for AS
was identified as Ube3a and it encodes for E6AP, an E3 ubiquitin ligase. Currently,
there is very little known about E6AP’s mechanism of action in vivo or how the lack of
this protein in neurons may contribute to the AS phenotype. Elucidating the mechanistic
action of E6AP would enhance our understanding of AS and drive current research into
new avenues that could lead to novel therapeutic approaches that target E6AP’s
various functions. To facilitate the study of AS, we have generated a novel rat model in
which we deleted the rat Ube3a gene using CRISPR. The AS rat phenotypically mirrors
human AS with loss of Ube3a expression in the brain and deficits in motor coordination
as well as learning and memory. This model offers a new avenue for the study of
Angelman syndrome.
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2.2 Introduction
Angelman syndrome (AS) is a rare neurogenetic disorder caused primarily by
alterations within the maternally inherited allele for UBE3A, encoding for an E3 ubiquitin
ligase. UBE3A undergoes neuron-specific imprinting, which transcriptionally silences
the paternal allele with an antisense transcript. This results in predominant maternal
UBE3A expression within the brain (Meng, Person, & Beaudet, 2012). Maternal
disruption of UBE3A results in a >95% reduction of neuronal UBE3A protein within the
CNS leading to the manifestation of AS symptoms. In peripheral tissue, there is biallelic
expression of UBE3A, with a >50% reduction of protein expression in AS patients
(Gustin, et al., 2010).
Angelman syndrome is characterized by severe cognitive and motor deficits,
seizures, abnormal EEGs, speech impairments, sleep disturbances, and a generally
happy demeanor (Williams, Driscoll, & Dagli, 2010). Approximately 70% of AS patients
have a genetic alteration comprised of a de novo deletion within 15q11-q13 on the
maternal chromosome. Additionally, UBE3A expression may be reduced by other
mechanisms such as imprinting defects of the maternal copy (~6%), paternal
uniparental disomy (~3%), and mutations within the maternal chromosome (~13%), all
of which can lead to AS development (Y. Jiang, Lev-Lehman, Bressler, Tsai, & Beaudet,
1999; Lalande & Calciano, 2007). Despite the profound and penetrant symptoms in AS,
there are no gross anatomical aberrations noted in either the AS human brain or the
current AS mouse model brain (Bird, 2014; Judson, et al., 2017; Williams, et al., 2006;
Williams, et al., 2010).
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Much of what is known about the AS condition is from studies conducted on the
murine model (Y. H. Jiang, et al., 1998). The AS mouse model, produced through an
exon 2 null mutation, has supported molecular research and refined drug discovery
since its introduction two decades ago (Y. H. Jiang, et al., 1998). While this model is
widely used and reported, there are notable challenges including, but not limited to,
strain influences and phenotypic inconsistency (Born, et al., 2017; Huang, et al., 2013).
This has led to interest in the generation of new models for AS which could more closely
reflect the human AS phenotype.
Traditionally, rats have offered a more preferable model of human disorders due
to greater similarities in human physiology. Rats, in general, have a much larger brain
and body size facilitating the utilization of a wider array of cognitive, social, and
biochemical techniques (Ellenbroek & Youn, 2016; Iannaccone & Jacob, 2009;
Kummer, et al., 2014). A larger size will also aid in facilitating some detailed
developmental, anatomical and physiological measurements which are not as feasible
in mice due to its smaller size. Rats have been highly characterized and exhibit higher
motor coordination and behavioral complexity, giving a more accurate assessment of
cognitive outcomes especially during a developmental time course (Ellenbroek & Youn,
2016; Iannaccone & Jacob, 2009; Kummer, et al., 2014). Within the pharmaceutical
industry it has become standardized to use the rat for a physiological and toxicological
model (Parasuraman, 2011). Thus, the use of a rat AS model may allow researchers to
better understand the AS condition and permit more accurate assessment of novel
therapeutic approaches in a superior model of AS.
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As mentioned previously, the majority of human AS cases arise from a large
deletion of the maternal UBE3A gene. The previous AS mouse model is limited to a 3
kb sequence deletion, including exon 2, resulting in a deletion of 100 N-terminal amino
acids of UBE3A and a frameshift inactivating all putative protein isoforms, which does
not reflect the majority of human AS manifestation (Y. H. Jiang, et al., 1998). Therefore,
we set out to produce a novel rat AS model which would encompass a deletion of the
entire Ube3a gene. In conjunction with this genetic alteration, the higher complexity of
the rat brain would allow for a refinement of a modeled AS phenotype to better
resemble the human condition.
Here, we report the generation of this novel rat model using CRISPR technology.
We compare the maternal gene knockout rat to its wild-type littermates, evaluating
Ube3a expression within the brain. We observed that there are no gross anatomical
aberrations within the brain structures. Western blotting indicates decreased Ube3a
expression within the brain, recapitulating what has been displayed in the AS mouse
model. General motor coordination, gait alterations, sociability and memory deficits
were characterized in this novel model.

2.3 Materials and Methods
2.3.1 Animals: CRISPR Cas 9 technique was used to generate a full deletion of the rat
Ube3a gene with ~90 Kb deletion. This was performed at Transposagen (Lexington,
KY). Four CRISPR guide RNAs were designed: 5’ CRISPR-1 target site
GGCCCTGCAGAGATGCAATC, 5’ CRISPR-2 target site GGAGCCCTCCGCCGGCA,
3’ CRISPR-1 target site TACCCTTCCCAGGCCCC; 3’ CRISPR-2 target site
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GCATTTCTAGTACATCATCC; two each to areas that flank the entire Ube3a region. A
vector that contained arms of homology that spanned the region to be deleted was also
included in the hopes that it may facilitate the deletion (this did not get incorporated into
the final clone). Almost 200 Sprague-Dawley embryos were injected (in two separate
cohorts) which resulted in 11 births. Animals were screened with the primers
Ube3aDelF1 (AACACCAAGCCTCTCTCAGC) and Ube3aDelR1
(ACCAGGCCTCAAAATTGACA) and two pups were identified as positive for the
deletion. These were then rescreened with Ub3aDelSpcfcF4
(ACATGGCTCTAAAAGAGTTCAGG) and Ube3aDelR1. Analysis of the region deleted
(~90Kb) is shown in Figure 1 and corresponds with CRISPR target 1 deletion.
DNA for genotyping was extracted from ear tissue using an alkaline lysis reagent
(10N NaOH, 0.5M EDTA, pH12). The sample was heated to 95 oC for 30min followed
by the addition of a neutralization buffer (40mM Tris-HCl, pH5). Initial genotyping
screening was performed using the following primers: for AS Ube3aDelSpcfcF6
[ACCTAGCCCAAAGCCATCTC] (0.4
[GGGAACAGCAAAAGACATGG] (0.4

M) and Ube3DelR2
M) which generates a 917 bp product; and for

wild type Rube1123 [TAGTGCTGAGGCACTGGTTCAGAGC] (0.4
[TGCAAGGGGTAGCTTACTCATAGC] (0.4

M) and Rube1606r

M) which generates a 459 bp product.

Cycling at 95 oC for 30 s/59 oC for 45 s/72 oC for 1.5 min with 35 cycles. Results are
shown in Figure 1b. To reconfirm initial genotyping results, additional primer pairs were
designed. This pair produced a smaller PCR product increasing accuracy with high
fidelity. An alternative set of genotype primers was designed to reduce the product size
for the deletion to 232 bp and to increase product efficiency and reproducibility, using
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Ube3aDelSpcfcF6 and AS-RR2 (TATTTTCCCCACCAAACACC) (0.4
genotyping, the wild type primers were included at 0.48

M). In this

M and the cycles performed

as above.

2.3.2 Breeding strategy: Ube3a deletion founder rats were back crossed with SpragueDawley rats for each generation. Original male founder rats were bred to obtain
paternal deletion offspring. Female offspring carrying the Ube3a deletion were then
bred with Sprague-Dawley males to produce maternal deletion offspring for
experiments. No differences were seen in litter sizes and genotypes if the dam had a
paternal deletion or maternal deletion. Therefore, maternal deletion females can be
used for breeding unlike the AS mouse where typically a paternal line is maintained for
generation of AS animals. Maternal breeding was used to generate the animals used in
this study. Animals were housed in a standard 12-hour light/dark cycle and supplied
with food and water ad libitum at the University of South Florida, and were housed in
groups of two per cage. All procedures were conducted in compliance with the NIH
Guidelines for the Care and Use of Laboratory Animals and approved by the
Institutional Animal Care and Use Committee of USF (approval number A4100-01).

2.3.3 Western blotting: Tissue samples were collected directly following rapid
decapitation. Followed by homogenization with (1:100) dilution of mammalian M-PER
(Millipore) supplemented with (1x) phosphatase and (1x) protease inhibitors (Thermo
Scientific). Protein concentration was measured using BCA Protein Assay Kit (Thermo
Scientific) and standardized to BSA. Laemmli buffer (Bio-Rad) and equal amounts of
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protein (3

g) were loaded into 15 well SDS-PAGE gel (10%). After transferring the gels

onto PVDF transfer membranes (Bio-Rad), blots were incubated at room temperature in
Revert total protein stain (Li-Cor Biosciences) for 5min following by 2x 3 minute
incubations in revert wash buffer. The revert was imaged and quantitated on the
Odyssey scanner. Blots were blocked in 1 x Tris-buffered saline with 0.1% Tween 20
(Sigma-Aldrich), and 5% non-fat dry milk (Lab Scientific) at room temperature (23 ± 2
°C) for 2 hours. The blots were then incubated in primary antibody, rat Ube3a (Millipore,
1:10,000) diluted in 5% non-fat dry milk mixed in Tris-buffered saline with 0.1% Tween
20 and left overnight at 4 °C. After incubation, blots went into three 10-minute washes in
Tris-buffered saline with 0.1% Tween 20. The blots were then incubated with goat antirabbit IgG-800CW (Li-Cor Biosciences) at 1:10,000. Membranes then went into three
ten minute rinses, as previously mentioned and were detected and analyzed using the
Li-Cor Odyssey and software. Individual T-tests were used to analyze for significance.

2.3.4 Immunohistochemistry: Rats (n=10) were deeply anesthetized with Somnasol and
perfused with PBS (0.01 M sodium phosphate–0.15 M NaCl, pH 7.2) and then freshly
prepared 4% paraformaldehyde in PBS. Brains were post-fixed for 12 h at 4 °C and
cryoprotected in 30% sucrose in PBS for shipping to Dr. Sumová. Coronal 30

m-thick

sections were cut and processed for free-floating immunohistochemistry using the
standard avidin-biotin method with diaminobenzidine (Vector Laboratories,
Peterborough, UK) as previously described (Sumova, Sladek, Jac, & Illnerova, 2002).
The anti-Ube3a mouse monoclonal antibody (Sigma, SAB1405408) was used as the
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primary antiserum (1:600). The sections of both genotypes were processed within one
assay and all sections were developed in diaminobenzidine for exactly the same time.

2.3.5 Functional Observational Battery (FOB): Home cage behavior was monitored
using a modified FOB from Moser and MacPhail (Moser & MacPhail, 1992). First, rats
were observed in their home cage for 60 s and behavior measurements recorded
(posture, palpebral closure, convulsions or tremors, biting, and vocalization). Next, rats
were moved to a clean cage containing a mark to indicate the midline of the cage and
singly housed for 10 minutes. Responses to handling were recorded (ease of removal
from cage, ease of handling, fur appearance). During the 10 minutes, total number of
crosses between sides, piloerection, number of audible vocalizations (not ultrasonic),
grooming episodes, eating episodes, drinking episodes, fecal bolus number, and urine
spot number were measured.

2.3.6 Weight measurements involved male and female animals being weighed every
seven days starting from the day of being weaned (day 21 post-natal) until one year of
age (WT n=18, AS n=11). It should be noted that 32 WT and 20 AS rats began weight
measurement at PND 21. 14 WT and 9 AS rats were removed for other research
purposes before week 52. These other animals matched the weights of those shown in
the graph up until they were euthanized.

2.3.7 Behavioral testing cohorts: All behavior testing occurred in the adult rats aged 3-4
months. Four cohorts of animals were used. Cohort 1: DigiGait, hind-limb clasping and
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novel object; Cohort 2: light/dark, y-maze, social approach, novel object, fear
conditioning; Cohort 3: rotarod, open field, elevated plus maze, y-maze, fear
conditioning; Cohort 4: open field, elevated plus maze and y-maze. Animals used in this
study were F3 to F5 generation from founders.

2.3.8 Hind limb clasping: Hind limb clasping was used as a marker for neurological
dysfunction and evaluated hind limb response to being suspended approximately 10 cm
above a smooth surface. Suspension was recorded by video camera for post-testing
analysis, which was performed by a separate technician, blinded to animal genotypes.
A scoring system ranged between 0 and 3. If assigned a 0, the animal consistently kept
legs away from abdomen splaying outward, considered typical hind limb posture. If
assigned a 1, the animal consistently retracted a single leg towards the abdomen or in a
rigid upward movement while the other splayed outward. If assigned a 2, the animal
partially retracted both hind limbs towards the abdomen. If assigned a 3, both hind limbs
were entirely retracted touching the abdomen or touching one another. All weanling
animals were tested 21 days post-natal (AS n=69 (30F, 39M), WT n=90 (45F, 45M))
and a subset of animals that underwent behavior testing were tested again at 4-5
months post-natal (AS n=16 (8M, 8F), WT n=18 (10M, 8F). An independent t-test was
used to analyze data.

2.3.9 Rotarod: General motor coordination and stamina was tested using the rotorod.
Animals were placed on a 7 cm diameter rotarod (Ugo Basile). The rod accelerated
from 4 rpm to 40 rpm over a five-minute time period. Rats were recorded for latency to
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fall off of the rotating rod over a two day period with four trials each day, each trial
separated by 30 min (3-4 months of age, AS n=10 (5F, 5M), WT n=10 (5F, 5M)). A
repeated measures ANOVA was used to analyze data.

2.3.10 DigiGait: Gait analysis was performed on a DigiGait (Mouse Specifics, Inc.) at a
speed of 15cm/sec. Rats were acclimated to an enclosed translucent treadmill before
initiation of the belt. Animals were typically recorded for less than 60 sec, to achieve at
least 3 sec of clearly recorded, consecutive steps. Gait analysis was analyzed using the
DigiGait program. Rats were 3-4 months of age with AS n=20 (11F, 9M) and WT n=18
(8F, 10M). An independent t-test was used to analyze data.

2.3.11 Open field: The open field is used as a standard test of general activity. Animals
are monitored for 15 minutes in a 60 cm square open field with a video tracking
software (Noldus), under moderate lighting (3-4 months of age, AS male n=8, AS
female n=8, WT male n=8, WT female n=8). General activity levels were evaluated by
Ethovision XT software (Noldus). An independent t-test was used to analyze data.

2.3.12 Light/Dark: Light/dark was conducted by placing the animal (3-4mo, AS n=14,
WT n=12) in a two-chambered apparatus for 15 min, recording the total time spent in
the light (40 by 30 cm) and dark side (40 by 22 cm), as well as total distance travelled
and number of entries into the light chamber (Ethovision XT, Noldus). An independent ttest was used to analyze data.
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2.3.13 Elevated plus maze: Rats (3-4mo, AS male n=8, AS female n=8, WT male n=8,
WT female n=8) were placed in elevated plus maze apparatus, consisting of two 50 by
10 cm open arms and two 50 by 10 cm closed arms facing each other with a 10 cm
square open area and allowed to explore for 15 min. Time spent in either the closed
arms or open arms as well as total distance travelled were recorded (Ethovision XT,
Noldus). An independent t-test was used to analyze data.

2.3.14 Novel object: Rats were acclimated to a 100 cm square open field box with two
inanimate objects placed at equidistant locations for 5 mins (two 20 cm tall clear
weighted plastic cylinders; 3-4 months of age, AS n=19 (10M, 9F), WT n=15 (7M, 8F).
This exploration was repeated after 30 mins. One hour after the second exploration, rats
were placed back into the same chamber with one of the objects being replaced for a
novel object (20 cm tall white glass weighted cuboid shaped container) and their
exploration recorded for 5 mins. Twenty-four hours later, the animals were again
recorded for 5 min in the box with one familiar (clear cylinder) and a third unfamiliar
object (~20 cm tall pink weighted plastic cuboid shaped object). General activity levels
as well as interaction times with the objects were evaluated by video tracking software
(Ethovision XT, Noldus). The results are presented as discrimination index which is
calculated as (time spent exploring the novel object minus time exploring the
familiar)/(total time exploring both novel + familiar) (Antunes & Biala, 2012). Derived
index scores, such as the discrimination index, correct for individual differences in total
exploration. A one-way ANOVA was used to analyze data.
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2.3.15 Social approach: Rats were exposed to a 100 cm square three-chamber
sociability apparatus (Noldus) containing empty wire cages in the corners of each of the
lateral chambers similar to previously described methods (Ku, Weir, Silverman, Berman,
& Bauman, 2016; Yang, Silverman, & Crawley, 2011). Rats at 3-4 months of age (AS
male n=6, AS female n=10, WT male n=9, WT female n=6) were acclimated to the
device for two trials lasting five minutes with a 15 minute inter-trial interval. On the third
trial, a novel rat was placed in one of the wire cages. To avoid any distress vocalizations
from the novel rat, which could alter tests results, the novel rat was trained in the wire
cage 24 hours before the test. This consisted of placing the animal in the wire cage 3
times for 30 min each separated by 30 min. The test subject explored the chamber on
the third trial for 5 minutes and latency of the nose engaged within 5 cm of the novel rat
was recorded (Ethovision XT, Noldus). An independent t-test was used to analyze data.

2.3.16 Y-maze: Y-maze was used to assess hippocampal-dependent spontaneous
alternation. Rats were placed in an apparatus containing 3 concentric arms (50 cm) and
allowed to explore for 8 min (3-4 months of age, AS n=11 (4M, 7F), WT n=15 (9M, 6F)).
Number of alternations (visits to each of the 3 arms in various orders), arm entries and
number of errors (number of direct re-visits or indirect re-visits were recorded using
video tracking software (Ethovision XT, Noldus). An independent t-test was used to
analyze data.

2.3.17 Fear conditioning: A 1-shock associative fear conditioning test was performed to
assess hippocampal- and amygdala-dependent learning and memory. The first day
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consisted of a training phase in which the animal explored a 25 cm square chamber
containing a wire grid under bright lighting (Stoelting). This chamber was located inside
a sound attenuation chamber. A 5-dB white noise was present inside the chamber
during training and contextual conditioning. After 3 min of exploration, rats were
presented with a 1000 Hz, 95 dB tone for 30 sec before receiving a mild foot shock (1.0
mA) at the last 2 sec of the tone. Rats remained in the chamber for an additional 3 min
before being placed back in an empty cage and then returned to the colony after all
testing was completed. Freezing was recorded as a measure of fear and was
designated as a lack of movement for 2 consecutive sec by Ethovision XT software
(Noldus). The second phase consisted of contextual and cued conditioning, which took
place 72 hours post-training. Rats were placed back into the chamber, but were not
exposed to any aversive stimuli, and the animals were monitored for 6 min. One hour
following contextual testing, animals were exposed to cued conditioning. The apparatus
environment was altered; changing the walls, floor, scent, lighting, as well as the clothes
and scent of handler. Rats were placed into this novel context and allowed to habituate
for 3 min. Following habituation, the same tone presented in training was administered
for 3 min and freezing behavior recorded. Test rats were 3-4 months of age with AS
n=11 (5M, 6F) and WT n=14 (7M, 7F). A two-way ANOVA was used to analyze both
training and cued fear conditioning and an independent t-test was used to analyze
contextual fear conditioning.

2.3.18 Statistics Data was assessed for outliers, by group, prior to analysis. All values
exceeding a minimum criteria of 2 standard deviations from the group mean were
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removed from subsequent analysis. An alpha of 0.05 was used for all main effects.
Family-wise error for complex effects was controlled using Tukey’s tests. Results are
presented as mean ± SEM. For behavioral tests comparing genotypes, an independent
t-test was used. For behavioral tests being compared over multiple times, a repeated
measures ANOVA was used. Statistical analysis was performed using SPSS software
or GraphPad Prizm software.

2.4 Results
2.4.1 Generation of Ube3a deletion rat model
The CRISPR/Cas9 system was utilized to generate a full deletion of the rat
Ube3a allele, on chromosome one. To increase the potential for deletion of the entire
Ube3a gene, four guide RNAs were designed to flank the entire Ube3a genomic region,
two at each end of the gene. To facilitate the deletion, an additional vector containing
arms of homology spanning the targeted region, were included and sequence verified.
To confirm deletion of the targeted region, PCR was performed, probing DNA with
primers spanning the deleted region. These primers annealed upstream of the 5’
CRISPR cut site and downstream of the 3’ CRISPR cut site. This identified 2 positive
hits. However, these primers did not account for random insertion of the vector
containing homology regions. Therefore, a second set of primers that span the deleted
region, but anneal outside of the vector arms was used to confirm deletion. This
confirmed the identification of the two deletion animals. The offspring positive for the
entire deletion were used as the founder line. The founder rats were bred with an
outbred CD® (Sprague Dawley) IGS rat colony (Charles River) to obtain heterozygous
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offspring. After confirmation of the first generation having the entire Ube3a gene
deleted, studies began utilizing the second generation rats. Although both rats
generated a large deletion of ~90 Kbp, there was a small difference of ~20bp between
the two founders. This study focused on characterizing the rat founder shown in Figure
1a.

Figure 2.4.1 Generation of Ube3a deletion rat model
a) Schematic of the Ube3a gene deletion including target sites for the CRISPR guide RNA’s and
actual sequence of the gene region below. Open arrowhead represents nucleotide sequence number
116587692 and the closed arrow represents nucleotide 116678172 of the rat chromosome 1 (NCBI
Ref. Seq.: NC_005100.4). b) Representative image of PCR results from primers used in initial
genotype screening generates a ~900 bp band for the AS deletion. Samples positive for the full
deletion alongside a WT control group are shown (WT primers generate a ~450 bp band). c)
Representative image of additional genotyping PCR with results for the AS full deletion (232 bp)
alongside a WT control group. d) Normal litter size and Mendelian distribution is seen regardless of
whether the dam had a paternal or maternal deletion for Ube3a (Paternal deletion dam, n=24;
Maternal deletion dam n=15). e) Weights measured every week up to one year of age. When
compared to WT (m+/p+) littermate controls n=18 (10M, 8F), AS (m-/p+) rats n=11 (6M, 5F) do not
have a significant difference in weight based upon sex.
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2.4.2 Breeding ability and observational behavior
Male founder rats were bred to obtain paternal deletion offspring. Female
offspring carrying the Ube3a deletion were then bred with Sprague Dawley males to
produce maternal deletion offspring for experiments. A comparison of the offspring from
dams that had a paternal deletion or maternal deletion demonstrated they both had
normal breeding ability with no differences in litter sizes and Mendelian distribution
(Figure 1d). Therefore, maternal deletion females were used for breeding to generate
AS animals without the need to maintain a paternal inherited dam line.
Animal weight was examined from day 21 (weaning) until 1 year of age. We observed
no differences in weight gain between the AS animals and their littermate controls
(Figure 1e). This is contrary to the mouse model where AS mice show significant weight
gain. It should be noted that AS patients do not typically demonstrate excess weight
gain like mice, thus the rat more closely emulates the patient condition (Clayton-Smith &
Laan, 2003; Williams, 2010).
To establish a baseline of behavior of the AS rats we performed a functional
observational battery. We examined arousal, cage crosses, grooming behavior, overall
eating and drinking, total fecal and urine spot counts. There were no significant
differences in these home-cage observational studies between all the groups of rats
tested, which included a comparison of male (m-/p+ and m+/p+) and female (m-/p+ and
m+/p+) animals.
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Figure 2.4.2 Characterization of Ube3a deletion rat CNS.
a) Representative anti-E6AP immunohistochemical images of the hippocampus of AS and WT brains
showing little to no E6AP detected in the AS rat brain. There was also no obvious gross anatomical
aberrations between groups. Scale bar = 200 m. b) Relative anti-E6AP staining for the rat
hippocampus shows a significant reduction in E6AP staining (AS n=10 (5M, 5F); WT n=10 (5M, 5F);
t(18)=17.88, p<0.05). c) Western blot with anti-E6AP antibody demonstrating a significant and near
complete reduction of Ube3a within various brain regions. d) Quantitation of western blot panel c
(relative to total protein from Revert staining). Hippocampus (HPC)striatum (STR prefrontal cortex
(PFC), rest of cortex (CX), cerebellum (CER), olfactory bulbs (OLF).

2.4.3 Expression of Ube3a in maternal-deficient model
Studies began by analyzing overall gross brain structure. Within the human AS
population, there are no obvious gross anatomical defects although some patients
exhibit microcephaly (Bird, 2014; Williams, et al., 2010). When looking at overall gross
structure of the rat brain, there are no obvious anatomical aberrations in the brain when
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comparing adult maternal-deficient rats and wild-type littermate controls at four months
of age.

Figure 2.4.3 AS rats exhibit hind limb clasping and alterations in gait.
a) Representative limb postures following tail suspension in both AS and WT rats (4 weeks postnatal). b) AS (21 d n=69 (30F, 39M), 4-5 mo. n=16 (8F, 8M)) display a significant increase in hind
limb clasping compared to WT (21 d n=90 (45F, 45M), 4-5 mo. n=11 (8F, 10M)) (21 d t(157)=13.03,
*p<0.001, 4-5 mo. t(32)=7.43, p<0.0001). c) AS rats display decreased latency to fall off of rotating
rod (n=10) during trials 1, 5, 6, 7, and 8. (AS n=10 (5M, 5F), WT n=10 (5M, 5F); F(7,126) = 9.989,
p<0.0005 d) AS rats display decreased hind limb propel time (time required for accelerating the
motion and continuing the forward motion) when compared to WT littermate controls (AS n=20
(11F, 9M), WT n=18 (8F, 10M); t(74)=3.908, *p<0.0005). e) There are no significant differences
between groups in swing time (time duration of swinging the paw without belt contact) (Swing forelimb t(74)=1.455, p>0.05; Swing hind-limb t(74)=2.13, p>0.05). f) Significant differences were
observed between groups in paw angle (absolute degree of paw angle) (paw angle fore-limb
t(74)=0.865, p>0.05; paw angle hind-limb t(74)=2.217, p<0.007). g) AS rats display an alteration in gait
symmetry when compared to WT littermate controls (t(36)=2.919, p<0.007) (gait symmetry: ratio of
fore limb stepping frequency to hind limb stepping frequency).
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To confirm reduction in E6AP protein expression in the AS rat we examined
homogenized tissue from the CNS by western blot analysis (Figure 2d and 2e). As
stated above, biallelic expression is seen in mammalian peripheral tissues, but in
neurons Ube3a expression predominately arises via the maternal allele due to the
paternal allele imprinting. As expected there is almost complete absence in protein
expression in all CNS regions tested (Figure 2). Immunohistochemical staining of the rat
brains for E6AP shows little to no E6AP staining in the AS animals compared to the
wild-type littermate control animals (Figure 2a-c).

2.4.4 General locomotor ability
Locomotor aberrations or ataxia are a prominent phenotype within the human AS
population as well as in AS mouse models (Grieco, Gouelle, & Weeber, 2018; Y. H.
Jiang, et al., 1998; Williams, 2010; Williams, et al., 2010). Hind limb clasping has been
used as an indicator of cerebellar ataxia and is an established phenotype in the AS
mouse (Lalonde & Strazielle, 2011; Mandel-Brehm, Salogiannis, Dhamne, Rotenberg, &
Greenberg, 2015). The maternal-deficient rats recapitulate this phenotype seen in the
AS mice, displaying a significant increase in hind limb clasping compared to wild-type
littermates (Figure 3a and 3b). This could suggest a cerebellar ataxia phenotype.
We sought to determine if the ataxia extended to motor coordination and motor learning.
The AS mouse model has demonstrated a significant deficit in rotarod leading us to
expect a similar deficit in the AS rat. On day two of rotarod, the AS rats displayed a
significant deficit in motor skills learning compared to wild-type littermates in latency to
fall off the accelerating rod (Figure 3c).
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To examine the AS rats gait in more detail we used the DigiGait. This system
allows quantification of both spatial and temporal gait parameters while the rats are
walking on a translucent, motorized treadmill. These parameters include propel time,
being defined as the time required to accelerate the motion and continuing that motion
forward. When an animal exhibits a shorter duration in propel time, they display a
greater strength and better control in accelerating that motion. The AS rats exhibit a
higher score than the wild-type littermates, indicating they have less strength and less
control in their propel ability (Figure 3d). Another parameter examined was swing time,
being defined as the duration of swinging the paw while walking without making contact
on the belt of the treadmill. There were no significant differences between groups in
swing time (Figure 3e). There was, however, a significant increase in the hind limb paw
angle, indicating that the AS rats placed their hind limbs at a more lateral-facing position
(Figure 3f). This finding relates well with an increase in propel time in that typical paw
angles require less propel time, as seen in the wild-type littermates. Finally, gait
symmetry was assessed. This is a ratio of forelimb stepping frequency to hind limb
stepping frequency. There was a significant difference with the AS rats having an
elevated stepping frequency when compared to wild-type littermates (Figure 3g). A gait
symmetry level of 1 indicates a 1:1 stepping frequency between fore and hind limbs.
These data demonstrate that the AS rat has a deficit in hind limb coordination.
To examine general locomotor activity and to examine for any anxiety phenotype,
we employed the open field (Denenberg, 1969), light/dark (Arrant, Schramm-Sapyta, &
Kuhn, 2013) and elevated plus maze behavioral tasks (Pellow, Chopin, File, & Briley,
1985). We found the AS rats do not have a significant difference in the light dark test
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compared to wild-type littermates (data not shown). Consistent with this, we observed
no differences in time spent in the open arms in elevated plus maze (Figure 4c). There
were no significant differences in time spent in the center of the open field (Figure 4a).

Figure 2.4.4 AS rats do not demonstrate an anxiety phenotype but have a deficit in learning
and memory.
a) No differences in time spent in center of open field chamber (AS n=16 (8M, 8F), WT n=16 (8M,
8F), t(26)=1.4, p>0.17). b) There was a significant differences between groups in total distance
traveled in open field (t(29)=2.295, p<0.05)). c) No differences were observed in elevated plus
maze testing (AS n=16 (8M, 8F), WT n=16 (8M, 8F), time in closed arms t(30)=0.926, p>0.36,
time in open arms t(30)=1.17, p>0.09). d) AS rats did not display a significant difference in percent
alternations in the Y-maze (AS n=11 (4M, 7F), WT n=15 (9M, 6F) (t(23)=0.217, p>0.77). e) AS
rats displayed a significant increase in the number of total errors made within the Y-maze
(t(23)=2.295, p<0.05). f) AS rats showed no difference in the number of arm entries (t(23)=1.19,
p>0.27).
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These results suggest that these animals do not display an obvious anxiety phenotype.
In distance traveled in the open field, we did observe a significant increase compared to
wild-type littermates, suggesting a possible hyperactive phenotype (Figure 4b).

2.4.5 Learning and memory
Hippocampal-dependent spontaneous alternation and associative learning and
memory testing were performed using the Y-maze and fear conditioning. For Y-maze,
animals were placed in the apparatus for 8 minutes. Arm entries and alternations were
recorded as well as total number of errors. Although there was no differences observed
in alternations, there was a significant increase in the number of errors in the AS rats
compared to their wild type littermates (Figure 4d-f).
Contextual and cued fear conditioning were performed to assess hippocampaldependent associative learning and memory. A one foot-shock paradigm followed by a
72-hour post-training contextual and cued test were utilized for this portion. No
significant differences were observed during fear conditioning training (Figure 5a).
However, 72 hours post-training, the AS rats have deficits in both cued and contextual
fear conditioning (Figure 5b-c). AS mice show a strain dependent deficit in contextual or
cued freezing (Born, et al., 2017; Huang, et al., 2013; Y. H. Jiang, et al., 1998).
Rats were tested in novel object recognition. Both WT and AS rats were tested 1 hour
and 24 hours after training with different novel objects to test their recognition memory.
It was found that the AS rats have no significant deficits in short or long-term object
recognition memory compared with wild-type littermates according to their
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Figure 2.4.5 AS rats display deficits in hippocampal dependent learning and memory.
a) AS rats showed no significant difference in percent freezing during fear conditioning training
(AS n=115M, 6F), WT n=14 (7M, 7F); F(1,23)=0.0165, p>0.05). b) AS rats show a significant
deficit in percent of time freezing 72 hours post-training during context testing (t(23)=5.054,
p<0.0002. c) AS rats displayed a deficit in cued fear conditioning 72 hours post-training
(F(1,23)=263, p<0.002). d) Novel object recognition showed no significant differences in
discrimination index with wild type controls (AS n=19 (10M, 9F), WT n=15 7M, 8F))
(F(3,88)=0.03, p>0.05). e) All animals exhibited preference for the novel rat compared to the
opposite, empty cage, but AS rats showed reduced interaction with the novel target rat
compared to WT rats (AS n=16 (6M, 10F), WT n=15 (9M, 6F)) (F(1,29)=12.53, p<0.002). f) This
reduction in interaction was predominantly due to the male AS rats (AS (n=6M, 10F), WT (n=9M,
6F) (t(12)=3.186, p<0.008)

discrimination index: ((Time(novel) – Time(familiar)) / (Time/novel + familiar)) (Figure
5d).
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2.4.6 Social approach
Social approach studies using an AS mouse model are complicated by strain
differences. AS 129 mice had low activity making assessment difficult, while B6 AS
mice had reduced exploration during the social approach testing but no significant
deficits in social approach (Allensworth, Saha, Reiter, & Heck, 2011; Huang, et al.,
2013). Therefore, we examined the rats in a social approach test. We observed that the
AS rats had an increased preference for interacting with the novel rat compared to the
empty chamber, but this interaction was significantly reduced compared to the wild-type
littermates (Figure 5e), suggesting a deficit in social interaction in the AS rat compared
to the wild type littermate. However, a comparison of sex differences in this task,
demonstrated that the differences we observed in this task are predominantly due to a
significant difference in male AS rats compare to the wild type littermates, with no
significant difference seen in the females (Figure 5f).

2.5 Discussion
Using the CRISPR/Cas9 system we have created a maternal Ube3a deletion AS
rat model resembling many of the deficits manifested in human AS, as well as the highly
characterized AS mouse model. This rat model displays normal breeding ability, litter
number, and Mendelian distribution. There have been many notable challenges with the
current AS mouse model such as, but not limited to, strain dependency and loss of
phenotype over time (Born, et al., 2017; Huang, et al., 2013). This has led to a high
demand for a more phenotypically consistent AS animal model which better resembles
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the human condition. The AS mouse model was created by a null mutation of exon 2 on
the maternal Ube3a gene. This mutation encompasses a small subset of the genetic
alterations that lead to the manifestation of human AS (~13%), while the majority of
human AS cases (~70%) are due to a large deletion within maternal chromosome 15
q11-13 including the complete deletion of the UBE3A gene (Y. Jiang, et al., 1999;
Lalande & Calciano, 2007). In our rat model we generated a deletion of the entire
maternal Ube3a gene. We have demonstrated that this model has a pervasive deletion
of the maternal Ube3a gene in the CNS. The remaining low levels that are detected via
western blotting are believed to be contributed by glial cell expression, which is similar
to the mouse model (Yamasaki, et al., 2003). Additionally, we did not observe any
obvious gross anatomical changes, as previously observed in the mouse model. The
AS rat model is genetically similar to most human AS cases demonstrating deficits in
UBE3A within the CNS. Given that our novel rat model genetically and biochemically
recapitulates AS, we sought to determine if it also displayed hallmark deficits in motor
coordination tasks. There have been no reports indicating a sex difference within the
human population of AS or within the AS mouse models. We chose to analyze sex
differences in behaviors to ensure there are no differences within the AS rat. We
analyzed differences in rotarod, open field, elevated plus maze and DigiGait and there
were no sex differences in any test. However, within social approach sex is a
confounding variable in wild type animals. At the age of the animals tested, there may
be a difference in motivation for males versus female rats. Considering this, we
examined for sex differences within social approach. No differences were observed
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between AS and WT females but there was a significant difference between AS and WT
males, with AS males showing reduced interaction.
Motor coordination deficits are a hallmark phenotype associated with human AS.
Hind limb clasping has been a well-documented phenotype associated with the AS
mouse model and has been shown to be indicative of cerebellar ataxia as well as
anxiety. Our rat model displayed prominent hind limb clasping as opposed to wild-type
littermates. This phenotype was present at an early age and persisted into adult hood.
To ensure that the increase in hind limb clasping is not due to an increase in anxiety, we
performed the light/dark behavioral task. We found that the AS rat did not show
increased anxiety in the light/dark task when compared to WT controls. Similarly, we did
not observe any indications of an anxiety phenotype in open field or elevated plus
maze. This suggests that the significant difference in hind limb clasping is likely due to
an ataxic phenotype.
We next evaluated this potential cerebellar deficit on the rotarod task, as motor
deficits are a hallmark phenotype in the AS mouse model. Like the AS mouse, we
observed a significant deficit in rotarod performance. It is worth noting that the AS
mouse model shows a significant increase in weight as they age compared to wild-type
mice (Ciarlone, Grieco, D'Agostino, & Weeber, 2016). Increased weight gain is only
seen in a small subset of the human population (Clayton-Smith & Laan, 2003; Williams,
2010). It is unknown if the weight gain in the AS mice is a significant confound in the
rotarod causing the mice to inaccurately demonstrate a deficit in motor coordination.
However, our AS rat model does not show a difference in weight gain from the wild-type
littermates, yet still demonstrated a significant deficit in rotarod performance. This
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suggests that the rotarod deficits seen in both models are likely due to an ataxic
phenotype, thus recapitulating the disease phenotype in humans. The weight gain in the
AS mice may confound other tasks such as open field distance travelled. It has been
reported that in certain strains of AS mice there is a significant reduction in distance
travelled (Born, et al., 2017; Huang, et al., 2013), but with the AS rats we observed a
significant increase in distance travelled, suggesting a more hyperactive phenotype.
Hyperactive behaviors have been reported in the human AS condition (Williams, et al.,
2010).
We also evaluated motor function using DigiGait, which can more closely analyze
gait parameters which rotarod cannot. Examination of spatiotemporal parameters in AS
patients walking demonstrated that the AS children exhibited shorter step length,
decreased cadence and consequently lower speed, higher stride width, and less time
spent in single support compared to neurotypical children (Grieco, et al., 2018). We
were able to determine that the AS rat model has significant alterations in gait
compared to wild-type littermates. We observed an increase in propel time which is an
indication of reduced strength and control of movements. The AS rats also had an
alteration in hind limb paw angle. Paw angle is also known as degree of external
rotation, thigh-foot angle (in people), toe in/out angle (in people), or splay angle. The AS
rats displayed an increase in paw angle indicative of an increased splaying of the hind
paws. More open angles of the hind paws are associated with ataxia, spinal cord injury,
and demyelinating disease (Powell, Anch, Dyche, Bloom, & Richtert, 1999). An
examination of gait symmetry (a ratio of fore limb stepping to hind limb stepping)
showed a significant increase, suggesting a reduction in hind limb movement compared

72

to the fore limbs. These DigiGait data imply that the AS rat motor deficit is likely due to a
problem in hind limb coordination and control. Thus, the AS rat can model the deficits in
motor coordination that are commonly reported in the AS population. This could be a
useful outcome measure for testing therapeutics that could improve the motor deficits in
AS.
The AS rat showed deficits in standard learning and memory tasks. Compared to
wild-type littermate controls we observed increases in the number of errors in Y-maze,
as well as a deficit in the fear conditioning task. We did not observe a difference in novel
object recognition, which has previously been reported for some AS mouse strains but
not all (Born, et al., 2017; Huang, et al., 2013). Contextual fear conditioning deficits are
also strain dependent, with 129 mice but not B6 mice exhibiting deficits (Born, et al.,
2017; Huang, et al., 2013). Typically there is not a deficit in cued fear conditioning in AS
mice (Born, et al., 2017; Daily, et al., 2011) but one group has reported a deficit in B6
mice (Huang, et al., 2013), suggesting that this phenotype is not consistent in the AS
mouse, which confounds its use especially between labs. Interestingly, we observed
deficits in both the contextual and cued responses in the fear conditioning task with the
AS rat. The hippocampal-dependent contextual deficit is greater than the cued deficit,
as may be expected from mouse studies, but the cued deficit present in the rat could
exemplify the greater complexity of the rat which allows more subtle deficits to become
apparent. This suggests that the AS rat may offer a better model for studying
therapeutic interventions for AS. Further investigation is required to examine aspects of
learning and memory such as hippocampal synaptic plasticity through long-term
potentiation and long-term depression in these animals.
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Although inbred strains offer genetic uniformity, the outbred stocks, known for
genetic variability are often used to potentially more closely mimic what one would find
in the human population. We used the outbred Sprague-Dawley rats with the goal to
represent more diversity and thus hopefully more translatability to the human AS
population. As discussed above, there are many advantages to using a rat model over a
mouse model to mimic a human disorder, including its genetic similarity (90% of rat
genes possess strict orthologues of the human genes (Gibbs, et al., 2004)) and its
closer resemblance to human physiology. The rat has a much higher level of complexity
within its physiological systems, more accurately reflecting human physiology than mice
(Iannaccone & Jacob, 2009). One example of this is Melatonin, an important mediator
for complex physiological functions including circadian regulation, sleep, and cognition
(which are all disrupted in AS). Most inbred mouse strains, including, C57BL/6, have
been reported to be deficient in melatonin, while rats similar to humans produce this
hormone (Ebihara, Marks, Hudson, & Menaker, 1986; Korf, Von Gall, & Stehle, 2003;
Roseboom, et al., 1998; Stehle, von Gall, & Korf, 2002). This can make the rat a much
more relevant model for neuropsychiatric disorders.
The creation of a novel AS model more accurately depicting the human condition
was in high demand and with advances in CRISPR/Cas9, we have been able to create
such a model. We have generated a novel AS rat which we believe recapitulates many
aspects of AS. This new model should offer avenues for increased exploration of AS
and advance our understanding of molecular targets of Ube3a thus expanding our
knowledge of the disease. This model offers a high potential utility for drug evaluation,
biomarker discovery, and will aid in the development and testing of novel therapeutic
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treatments. The rat would offer a model to test both efficacy and toxicology with in one
model animal.
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CHAPTER THREE:
IDENTIFICATION OF UBE3A PROTEIN IN CSF AND EXTRACELLULAR SPACE OF
THE HIPPOCAMPUS SUGGEST A POTENTIAL NOVEL FUNCTION IN SYNAPTIC
PLASTICITY

3.1 Abstract
Disruptions to the maternally inherited allele UBE3A, encoding for an E3 ubiquitin
ligase, leads to the manifestation of Angelman Syndrome (AS). While this disorder is
rare, the symptoms are severe and lifelong including but not limited to: intractable
seizures, abnormal EEG's, ataxic gait, lack of speech, and most notably an abnormally
happy demeanor with easily provoked laughter. Currently, little is known about the
neurophysiological underpinnings of UBE3A leading to such globally severe
phenotypes. Utilizing the newest AS rat model, comprised of a full UBE3A deletion, we
aimed to elucidate novel mechanistic actions and potential therapeutic targets. This
report demonstrates for the first time that catalytically active UBE3A protein is
detectable within cerebrospinal fluid (CSF) of wild type rats but distinctly absent in AS
rat CSF. Microdialysis within the rat hippocampus also showed that UBE3A protein is
located in the interstitial fluid of wild type rat brains but absent in AS animals. This
protein maintains catalytic activity and appears to be regulated in a dynamic activity‐
dependent manner.
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3.2 Introduction
Angelman syndrome (AS) is a rare neurological disorder afflicting approximately
1 in every 15,000 people (Clayton-Smith & Pembrey, 1992; Steffenburg, Gillberg,
Steffenburg, & Kyllerman, 1996)(Petersen, Brondum-Nielsen, Hansen, & Wulff, 1995).
The clinical manifestations of AS are severe and lifelong with potential for progression.
AS patients have a wide range of symptoms including, but not limited to, seizures,
ataxia, severe cognitive and motor impairments, lack of speech, sleep disturbances,
hyperactivity, and a markedly abnormal happy demeanor (Williams, Driscoll, & Dagli,
2010) There are currently no approved treatments for AS, and few therapeutic options
are available to abate symptoms. Due to the rarity of AS, diagnosis is often delayed for
years despite symptoms arising as early as 6 months of age (Williams, et al., 2010).
A maternal deficiency in UBE3A gene expression leads to the manifestation of
AS. UBE3A is biallelically expressed during development but postnatally the paternal
UBE3A gene undergoes neuronal specific imprinting, which results in loss of paternal
expression making the maternal allele the only source of UBE3A within neurons. AS
patients, who lack maternal UBE3A expression, have a near to complete loss of UBE3A
within the brain leading to globally severe symptoms which persist into adulthood
(Burette, et al., 2018).
The mechanism behind UBE3A leading to such severe symptoms in AS, has
remained unclear. It has long been thought that UBE3A is isolated intracellularly with its
primary function being the contribution to the proteasome degradation pathway. An
example of this is UBE3A’s regulation of the small conductance calcium-activated
potassium channel type 2 (SK2). Sun et al (2015) demonstrated that UBE3A can
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regulate SK2s levels via ubiquitination and the lack of UBE3A results in an increase in
SK2 levels and disruption of long-term potentiation (LTP) (Sun, et al., 2015). However,
recent reports have demonstrated that UBE3A has a multitude of functions outside of
ubiquitinating substrates, with critical regulatory cytoplasmic and nuclear functions
(Khatri & Man, 2019; Lopez, et al., 2017; Lopez, Segal, & LaSalle, 2018). UBE3A has
been shown to have a broad neuronal distribution localizing in axon terminals,
mitochondria, as well as euchromatin-rich nuclear domains (Burette, et al., 2017;
Burette, et al., 2018). UBE3A-associated proteins have been shown to be involved in
many essential processes including, intracellular trafficking, DNA replication, translation,
as well as centromere regulation (Martinez-Noel, et al., 2018).
UBE3A has been shown to form many complexes with critical proteins such as
the Minichromosome Maintenance (MCM) Complex Component 6 forming the MCM
complex. This complex is important in DNA replication and it also interacts with
Polymerase II which has been suggested in facilitating transcription via chromatin
remodeling (Yankulov, et al., 1999). Upon binding to HERC2 and NEURL4, UBE3A
forms a complex HUN (HERC2, UBE3A, and NEURL4) which is believed to be involved
in DNA replication, transcription, and repair (Martinez-Noel, et al., 2012). MTOR is
another UBE3A binding partner, which has been established as being involved in cell
cycle regulation, cellular metabolism, and has been implicated in long-term synaptic
plasticity and memory (Sui, Wang, & Li, 2008)(Man, et al., 2003). UBE3A has been
shown to be a coactivator of nuclear hormone receptors inducing nuclear localization
and transcriptional regulation, specifically down regulating estradiol-induced expression
of some genes. A major gene that is downregulated via this pathway is ARC, which is
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involved in the internalization of AMPA receptors. In the AS mouse, results demonstrate
there is an overexpression of ARC in neurons leading to detrimental AMPA receptor
internalization (Greer, et al., 2010; Kuhnle, Mothes, Matentzoglu, & Scheffner, 2013). All
of these findings demonstrate UBE3A has a prominent nuclear role and could be a key
regulatory protein in transcription.
It is also becoming increasingly clear that UBE3A is involved in many pathways
affecting overall cognitive function leading to the idea that there may not be a single
mechanism behind the manifestation of AS. Recent reports implicate alterations in
UBE3A activity contributing to the manifestation of other diseases such as Huntington’s,
Parkinson’s, and Alzheimer’s, making UBE3A a protein of high interest (Olabarria, et al.,
2019)(Salminen, Read, Hurd, & Crespi, 2019)(Maheshwari, et al., 2014). Understanding
novel roles of UBE3A is of the upmost importance for the identification and targeting of
potential therapeutic pathways.
Here, we report the novel finding that UBE3A is present within the cerebral spinal
fluid (CSF) of WT rats with an absence in AS rats. Furthermore, we demonstrate that
catalytically active UBE3A is found in the extracellular space of the brain, implicating a
potential functional role outside of the cell. We also observed that extracellular UBE3A
appears to be under dynamic activity-dependent regulation, which would further support
the idea that UBE3A has an extracellular functional role.

3.3 Materials and Methods
3.3.1 Animals: UBE3A maternal deletion AS rats, described previously (Dodge, et al.,
2020). Heterozygous female rats were bred with wild type male rats to produce
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maternal-deficient AS offspring and age matched wild type litter mate controls. Animals
were genotyped as described previously (Dodge, et al., 2020). UBE3A null mutation
C57Bl/6 AS mice, described previously (Jiang, et al., 1998). Animals were obtained
through breeding of heterozygous female mice with WT males to produce maternaldeficient AS offspring and age matched wild type litter mate controls. Animals were
housed in a standard 12-hour light/dark cycle and supplied with food and water ad
libitum at the University of South Florida, and were housed in groups of two per cage.
All procedures were conducted in compliance with the NIH Guidelines for the Care and
Use of Laboratory Animals and approved by the Institutional Animal Care and Use
Committee of USF (approval number A4100-01).

3.3.2 Rat and mouse CSF collection: Animals were anesthetized with an intraperitoneal
injection of Somnasol (0.1mL/450g) and placed into a stereotaxic unit. Their head was
immobilized with ear bars and fur was removed from neck, aseptic technique was used
to clean the area. A 27x3/4” gauge butterfly needle (Exel) was placed into the cisterna
magnum and CSF was pulled through tubing with a 1 mL syringe (BD). Samples were
snap frozen on dry ice and stored in -80⁰C until use. Rats wild type n=9 (3M/6F), AS
n=9 (5M/4F); mice wild type n=5 (2M/3F), AS n=6 (4M/2F). From rats 50-150
was obtained and for mice 10-20

L of CSF

L of CSF was collected per animal. For rat samples

we performed a hemoglobin ELISA (Eagle Biosciences, RT021-K01) as per
manufacturer’s instructions to determine if CSF samples were contaminated with blood.
Samples with hemoglobin greater than 500 ng/mL were excluded from analysis (all wild
type samples were <200 ng/mL). For western blots 20
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L of rat CSF and 10

L of

mouse CSF was loaded used for analysis. A rat hemoglobin ELISA (Eagle Biosci. Inc,
Nashua NH) was used to determine that low levels of blood were present in the
samples collected.

3.3.3 Western blotting: CSF (or dialysate) as mixed with an equal amount of loading buffer
(2x lamalie buffer, BME) and heated to 95 °C for five minutes. Samples were loaded into
an 18 well SDS-PAGE gel (Bio-rad 4-15%). Immediately after transferring the gels onto
nitrocellulose transfer membranes (Bio-Rad), blots were incubated in Revert total protein
stain (Li-Cor) at room temperature for 5 min. Followed by 2x3 minute incubations in revert
wash buffer (33.5 mL CH3COOH, 150 mL CH3OH, 316.5 mL ddH2O). The blot was
imaged for total protein (Odyssey, 700 nm). After imaging, the blot went through 3x5 min
washes in 1X TBST (1 x Tris-buffered saline with 0.1% Tween 20 (Sigma-Aldrich)). Then
blocked in 1X TBST solution with 5% non-fat dry milk (Lab Scientific) at room temperature
(23 ± 2 °C) for 2 hours. The blots were then incubated in primary antibodies, anti-UBE3A
(Sigma (E8655) or Millipore (MABS1683), 1:2,000), anti-S5A (Boston Biochem (AF5540),
1:10,000) diluted in 5% non-fat dry milk mixed in Tris-buffered saline with 0.1% Tween 20
and left overnight at 4 °C. After incubation blots went into three 10-minute washes in Trisbuffered saline with 0.1% Tween 20. The blots were then incubated with goat anti-rabbit
(or anti-mouse) LICOR IRdye IgG (H+L) (800cw, Neta Scientific) at 1:5,000. Membranes
then went into three ten minute washes, and then imaged (Odyssey, 800nm). Protein
band density was analyzed using Image Studio Software. Total protein (Revert Li-Cor)
was used as the standard control when performing densitometry and data expressed as
the ratio of UBE3A band intensity/total protein intensity. Boston Biochem recombinant
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UBE3A (E3-230) protein was used as a standard to approximate UBE3A protein amounts
in samples. Recombinant UBE3A protein (2-80 ng) was loaded onto the same western
blot as CSF (20-30 L) and microdialysate and a standard curve was generated to
estimate the amount of protein in each sample.

3.3.4 Immunoprecipitation Sepharose-G beads (25 L Abcam) were rinsed with 1xPBS
and centrifuged (1,000 RPM, 4⁰C, 2 min). The rinse was repeated three times. Antibody
(Sigma α-UBE3A 1:10) was added to rat CSF (25 L) or hippocampal dialysate (15 L)
and incubated at 4⁰C for 3 hours with rocking. Following incubation, Sepharose-G
beads were added to the sample/antibody mixture and incubated at 4 oC for 3 h. For in
vitro activity assays, the sample was centrifuged and the supernatant collected and
used in the in vitro assay. For mass spectrometry analysis the samples were
centrifuged and supernatant was removed. The beads were washed with 1xPBS. Beads
were then submerged in 50 µl of 30 mM ammonium bicarbonate (pH 8) followed by
denaturation at 95oC for 5 min. After allowing to cool to room temperature (23 ± 2 °C)
beads were reduced and alkalated with 45 mM DTT (to a 1/10 solution and incubated at
60oC for 30 min) and 110 mM IAA (1/10 solution and incubated at room temperature, in
the dark for 20 minutes) respectively. 200 ng of trypsin was added to each sample and
the final volume brought up to 100 µl with 30 mM ammonium bicarbonate and allowed
to digest over night at 37oC. The following morning an additional 200 ng of trypsin was
added and allowed to digest for an additional 2 h. Samples were then acidified with a
TFA to a final concentration of 1%, put on ice for 15 min, then spun down at 10,000 rpm
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room temperature for 10 minutes, and the resulting supernatant was cleaned using a
Millipore ™ ziptip and samples used in mass spectrometry.

3.3.5 Mass Spectrometry: Samples were then reduced with a final concentration of 20
mM dithiothreitol, heated at 95°C for 10 minutes, then cooled before alkylating cysteines
with the addition of 40 mM iodoacetamide, final concentration. Samples were then
incubated in the dark for 20 minutes at room temperature, followed by the removal of
any undissolved matter by centrifugation at 17,000 x g for 10 minutes. The clarified
supernatant was transferred to a new tube followed by addition of 12% aqueous
phosphoric acid at 1:10 for a final concentration of 1.2% phosphoric acid. Six times the
volume of S-TRAP protein binding buffer consisting of 90% aqueous methanol, 100 mM
Tris, pH 7.1 was then added to the acidified protein and mixed well. The S-Trap micro
column (Protifi brand) was placed in a 1.7mL tube in order to retain flow-through. The
sample mixture was then added into the micro column 200 µl at a time, followed by
centrifugation of the micro column at 4,000 x g for 1 minute, removal of the flowthrough, and repeating the process until the entire sample had passed through the STrap. Protein bound within the protein-trapping matrix of the spin column was washed
with 150 µL S-Trap buffer; centrifugation and removal of the flow through was then
repeated for a total of 3 rounds. The S-Trap was then moved to a clean 1.7 mL sample
tube for proteolytic digestion where 20 µL of digestion buffer containing 30 mM
ammonium bicarbonate with 1 µg. Trypsin/Lys-C protease (Promega) was added to the
micro column. To ensure no air bubbles remained between the protease digestion
solution and the protein trap, gel loading tips were used. The S-Trap micro column was
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then capped to limit evaporative loss without forming an air tight seal and incubated in a
heat block for 37oC overnight. After digestion, peptides were eluted first with 40 µL of 50
mM TEAB and centrifuges at 4000 x g for 1 min. An additional 40 µl of 0.2% formic acid
in LC-MS grade H2O was added and then centrifuged at 4,000 x g for 1 min. Finally, to
recover hydrophobic peptides, a final elution of 35 µL of 50% acetonitrile containing
0.2% formic acid was added with a final centrifugation at 5000 x g for 5 min. All eluates
were collected in the same tube to prevent transfer loss. Eluted peptides were
centrifuged under vacuum until dryness and then resuspended in 0.1% formic acid in
H2O. Samples were sonicated 10 minutes in a water bath and centrifuged 17,000 x g
for 30 min to fully pull down any insoluble particulate before transferring the clarified
peptide supernatant into autosampler vials.

3.3.6 LC-MS analysis: Peptides were characterized using a Thermo Q-exactive-HF
mass spectrometer coupled to a Thermo Easy nLC 1200. Samples separated at 300
nl/min on an Acclaim PEPMAP 100 trap (75 m, 25 cm, c18 3 m, 100A) and an
Acclaim PEPMAP 100 Column (75 m, 25 cm, c18, 100A) using a 120 minute gradient
with an initial starting condition of 2% B buffer (0.1% formic acid in 90% Acetonitrile)
and 98% A buffer (0.1% formic acid in water). Buffer B was increased to 28% over 90
minutes, then up to 40% in an additional 10 minutes. High B (90%) was run for 15
minutes afterwards. The mass spectrometer was outfitted with a Thermo nanospray
Flex source with the following parameters: Spray voltage: 2.24, Capillary temperature:
200dC, Funnel RF level=40. Parameters for data acquisition were as follows: for MS
data the resolution was 60,000 with an AGC target of 3e6 and a max IT time of 50 ms,
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the range was set to 400-1600 m/z. MS/MS data was acquired with a resolution of
15,000, an AGC of 1e5, max IT of 50 ms, and the top 30 peaks were picked with an
isolation window of 1.6m/z with a dynamic execution of 25s. Resulting data was
searched using Thermo Proteome Discoverer 2.2 software. A fully reviewed Mouse
database was downloaded from Uniprot which was used in the Sequest HT search. A
full trypsin digestion with a maximum of 2 missed cleavages was selected including a
precursor mass tolerance of 10 ppm and a fragment mass tolerance of 0.02 Da.
Modifications included oxidation, n-terminal acetylation, and carbamidomethylation.
The resulting peptides were then filtered for high confidence and validated with a
confidence threshold of 0.01 (Target FDR).

3.3.7 Ubiquitination Assay: E6AP Ubiquitin Ligase Kit - S5a Substrate, Boston Biochem
(#K-230) was used to test activity and performed as per manufacturers’ instructions.
Tubes with 46 L assay volume were created each containing 1x reaction buffer, 1X
Mg2+-ATP, 1X E1 enzyme, 1X His-S5A substrate, 1X E2 enzyme (UBE2D3), 28 L of
dialysate (or CSF n=10), and 1x ubiquitin. The reaction begins as soon as the ubiquitin
is added into the tubes. Assays were then incubated at 37 oC. Initial testing of the assay
used 9 separate time points over 9.0 h. Upon establishment of the assay, the number of
time points was decreased to three time points (over 2 h). The activity was terminated
by addition of SDS PAGE sample loading buffer with 1M dithiothreitol (DTT) followed by
quickly freezing on dry ice. These samples were then heated to 95 oC for 5 min and ran
on a western blot (Sigma α- UBE3A 1:2,000, α-S5A 1:1,000 Boston Biochem K-230 kit).
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3.2.8 Human CSF collection and Hemoglobin ELISA: Neuro-typical human CSF
samples were purchased from Innovative Research Inc. (Novi, MA) (male (41yrs), and
one pooled sample) and Discovery Life Sciences (Huntsville, AL) (female (26yrs) and
male (31 and 34yrs)). AS human samples were obtained with the coordinated
assistance of the Foundation for Angelman Syndrome Therapeutics (FAST).
Hemoglobin levels were analyzed to determine red blood cell contamination using the
hemoglobin ELISA kit from Abcam as described by the manufacturer (Cambridge, MA,
USA). Samples were excluded if hemoglobin levels were above 200 ng/mL
(Neurotypical n=5, AS n=3). Western analysis of human CSF (30 L) was performed as
for the rat CSF samples.

3.3.9 Microdialysis with associative fear conditioning: The procedure began with a
survival stereotaxic surgery on 4-5 month old rats. Animals were given a subcutaneous
injection of analgesic (Carpofen, 10mg/kg) 30 min prior to surgery. The rats were
anesthetized with Isoflurane (3% induction, 1.5-2.0% maintenance) and animals placed
on a WPI stereotaxic frame. A guide cannula (Amuza) was inserted into their left
hippocampus (5.6mm post bregma, +5.0 lateral, and 3.0 ventral from dura). The rats
were singly housed and allowed to recover for two days, to allow a decrease in
inflammatory response and recovery of the blood-brain barrier. Following recovery, rats
were placed in the universal microdialysis cage (BASi) allowing them to move freely
during collection. A 4 mm probe (Amuza) was inserted within the guide cannula at the
beginning of the day and allowed to equilibrate for two hours before collecting samples.
This timing was chosen from previous studies reporting that this timing allows for stable
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baseline measurements, reformation of the blood-brain barrier, and responsiveness to
cognitive load (McNay, Fries, & Gold, 2000)(McNay, et al., 2010). Sterile filtered artificial
cerebral spinal fluid with 2% BSA (Sigma) was perfused through the probe at a rate of
1.5 L/min. The first group of control animals (termed baseline) (n=7, 3M/4F) were
placed in the microdialysis chamber and dialysate samples were collected for 8 hours.
For the two test groups (shock and no shock), baseline microdialysis measurements
were collected for 1.5 h, immediately prior to testing conditions. The animals selected
for fear conditioning (shock group) (n=8, 5M/3F), were placed into a fear conditioning
apparatus (Ugo Basile) and allowed to habituate for three minutes. A 95 dB tone was
played for 30 sec with a foot shock (1 mA) being applied at the last two seconds of the
tone. The animals were allowed to recover in the fear conditioning chamber for 90 sec
and then placed back into the microdialysis universal cage for the remainder of the 6.5
hour collection time. For the no shock controls (n=9, 6M/3F), following the 1.5 h
dialysate collection for baseline, animals were placed in the fear conditioning apparatus
and allowed to explore for 3 min with no tone or shock applied. Following exposure to
the chamber the animals were placed back into the microdialysis universal cage for the
remainder of the 6.5 hour dialysate collection. Animals were euthanized at the end of
sampling.

3.3.10 Statistics: Data was assessed for outliers, by group, prior to analysis. All values
exceeding a minimum criteria of 2 standard deviations from the group mean were
removed from subsequent analysis. An alpha of 0.05 was used for all main effects.
Results are presented as mean ± SEM. For microdialysis comparing averaged baseline
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measurements to each time point, an independent t-test was used. Statistical analysis
was performed using SPSS software.

3.4 Results
3.4.1 UBE3A is present in CSF
We recently published on the creation a novel AS rat model [Dodge et al., 2020],
which has allowed for easier exploration of CSF for analysis due to the larger volumes
that can be obtained. In our endeavors to find a potential biomarker, we are the first to
identify that wild type rats, but not AS rats, have UBE3A present in their CSF (Fig. 1A).
This was further demonstrated in the AS mouse model (Fig. 1B). Western blot analysis
of neuro‐typical human samples (n = 5) also demonstrated the presence of UBE3A in
CSF (Fig. 1C). Western analysis using known amounts of recombinant UBE3A as a
standard curve (2–80 ng), we estimate the amount of UBE3A protein in the human CSF
to be ~100 ± 7 ng/mL (Fig. 1). Further confirmation of the presence of UBE3A protein
was achieved by using immunoprecipitation followed by mass spectrometry analysis.
Through mass spectrometry we identified 22 peptide fragments which belonged to rat
UBE3A (aligning to 13 different regions), thus definitely confirming the identity of UBE3A
by western analysis. Peptides identified are shown in Figure 2. One peptide
corresponds to a region on isoform 1 that is not present in isoform 3, suggesting that at
least some of the protein present is isoform 1. Further work is required to determine if
only one specific isoform is present.
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Figure 3.4.1 UBE3A is located in the cerebrospinal fluid and extracellular space of the brain.
a) Representative image of western blot of individual rat CSF samples using anti-UBE3A antibody. AS
rats have a significant reduction in UBE3A compared to WT rats. b) Representative image of individual
mouse CSF western blot using anti-Ube3a. AS mice have a significant deficit in CSF UBE3A compared to
WT littermates. c) Representative image of individual neuro-typical human CSF western blot. d)
Representative image of UBE3A dialysate western blot demonstrating presence of UBE3A in the
hippocampal extracellular space. e) Quantitation of anti-UBE3A in rat CSF relative to total protein levels
by revert (WT n=9 (3M/6F), AS n=9 (5M/4F), t(16)=7.366, p<0.0001). f) Quantitation of anti-UBE3A in
mouse CSF relative to total protein levels by revert (WT n=5 (2M/3F), AS n=6 (4M/2F), t(9)=4.898,
p<0.0001). g) Amount of UBE3A protein present in human CSF (Neuro-typical n=5) using a standard
curve of recombinant human UBE3A protein (Boston Biochem). h) Quantitation of anti-UBE3A in rat
hippocampal dialysate relative to total protein levels by revert (WT n=25 (14M/10F), AS n=4 (3M/1F),
t(27)=4.4.73, p<0.0001). Error bars represent SEM.

It is exceedingly difficult to obtain human AS CSF samples, although we obtained
3 AS CSF samples to date. Our initial sample presented negative by western analysis,
however, the latter two samples tested positive by western analysis (data not shown).
This was likely due to contamination of blood in the CSF samples as indicated by
significant levels of hemoglobin determined by ELISA (>800 ng/mL). This unfortunately
has meant that we cannot conclusively confirm that results observed in the AS rat in the
human condition. The neuro‐typical human samples used for analysis showed no
significant contamination of hemoglobin within the CSF.
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Figure 3.4.2 Rat isoform 1 amino acid sequence from NCBI (GI:394025712).
Peptide sequences that were identified from mass spectrometry analysis are indicated by a line under the
protein sequence. Twenty‐two different peptides covering a significant proportion of the protein were
identified. Bold M indicates start of isoform 3.

Discovery of UBE3A protein in the CSF lead us to ask the question of where this
protein may originate. Since Hippocampal dependent learning and memory deficits are
very prominent in AS, we wanted to see if UBE3A protein is located in the extracellular
space of brain regions known to be important in learning and memory. Focusing on the
hippocampus, microdialysis was utilized to sample interstitial fluid in awake, freely
moving, WT rats. Samples were collected every 30 min for 8 hr and western blotting was
used to demonstrate the presence of UBE3A protein in the extracellular space of the
hippocampus (Fig. 1D). Utilizing the AS rats, we confirmed by microdialysis, that
UBE3A protein was greatly reduced in the extracellular space (Fig. 3D).
3.4.2 Activity of extracellular UBE3A
We wanted to determine if UBE3A protein, within the extracellular space and
CSF, maintains its catalytic activity for self‐ubiquitination as well as ubiquitination of
substrates. We utilized a ubiquitination kit from Boston Biochem containing a well‐
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known UBE3A substrate, S5A. Due to the difference in molecular weights of UBE3A
(100 kDa) and S5a (50 kDa), the same blot was used to probe for self‐ubiquitination, as
well as s5a, without concerns of stripping the blot or antibody interactions. As
subsequent 8 kDa ubiquitins are added to the proteins, the molecular weights of S5a
and UBE3A gradually increase over time. Figure 3A,B demonstrates that the UBE3A
protein present in both the CSF and hippocampal dialysate were active in ubiquitinating
both the S5A substrate and UBE3A.
Previous reports demonstrate the presence of ubiquitin, and proteasomes within
neuro‐typical interstitial fluid which could implicate other functioning E3 ligases within
the extracellular space [Sujashvili, 2016; Sixt & Dahlmann, 2008]. To confirm our assay
is showing an increase in ubiquitination from UBE3A protein, dialysate samples were
immuno‐depleted of UBE3A. Microdialysate samples were incubated with anti‐UBE3A
protein antibody and Sepharose G beads. The remaining immuno‐depleted supernatant
was ran through the assay. With UBE3A protein immuno‐precipitated, UBE3A protein
was not detected and the S5A band intensity remained unchanged over time, indicating
that the previously observed ubiquitination was due to the presence of UBE3A activity
(Fig. 3C). Similarly, assaying microdialysate from AS rats showed no UBE3A protein
and no change in the S5A substrate band (Fig. 3D). As expected, removal of ATP from
the assay abrogated ligase activity (Fig. 3B). These results demonstrate extracellular
UBE3A protein within dialysate as well as in CSF, maintains its catalytic activity,
undergoing self‐ubiquitination, as well as ubiquitination of substrates.
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Figure 3.4.3 UBE3A maintains its catalytic activity within the CSF and hippocampal extracellular
space.
(A) Representative image of rat CSF ubiquitination assay western blot at 3 different time points (min) (n =
12, 10M/2F); α‐UBE3A Sigma, α‐S5A Boston Biochem). (B) Representative image of hippocampal
dialysate ubiquitination assay western blot (n = 2, 1M/1F). (C) Representative image of rat WT dialysate
with UBE3A immuno‐precipitated (n = 1M). (D) Representative image of AS rat dialysate ubiquitination
assay western blot at 3 different time points (n = 2, 1M/1F). (E) Quantification of S5A 40 kDa band
intensity, expressed as percentage of zero time value, for each assay.

3.4.3 Extracellular UBE3A Is Under Activity Dependent Regulation
It has previously been demonstrated in WT mice that Ube3a gene expression
changes with learning and memory tasks, in particular fear conditioning [Filonova,
Trotter, Banko, & Weeber, 2014]. To determine if this increased UBE3A expression is
associated with a concomitant increase in secretion of UBE3A protein during learning
tasks, microdialysis in conjunction with fear conditioning was utilized. A control group
was maintained in the microdialysis chamber with no exposure to the fear conditioning
chamber. As a second control we placed a group of animals in the fear conditioning
chamber without applying the tone or shock, termed “no shock” group. Dialysate was
collected every 3 min for 8 hr following 2 hr of habituation to the microdialysis chamber.
Animals that were subjected to the fear conditioning chamber were initially placed in the
microdialysis chamber for 3.5 hr with 1.5 hr of baseline recordings. In control animals
that were maintained in the microdialysis chamber only, there was no change in the
basal level of secreted UBE3A protein over the 8 hr of sampling (Fig. 4A). We found that
following exposure to the fear conditioning chamber in the no shock group, there is an
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immediate significant increase in UBE3A protein after exposure to the novel chamber
(Fig. 4B). However, there was a rapid decline to baseline levels within 60 min. In the
shock treatment group where the animals were subjected to the complete fear
conditioning paradigm, there was a significant increase at 2.5 hr time point following the
fear conditioning paradigm which persisted for ~3.5 hr (Fig. 4C). These data suggest
that release of intracellular UBE3A protein is activity dependent. Thus, secreted UBE3A
protein and its ubiquitination activity could have a functional role in learning and
memory.
3.5 Discussion
With the generation of the novel AS rat model, we were able to more easily
analyze CSF for UBE3A protein due to the larger volumes that can be collected. In
these efforts, we are the first to identify UBE3A protein is present in wild type rat CSF
and not in AS rat CSF. Alongside western blot analysis, we used mass spectrometry to
confirm the presence of UBE3A protein in the CSF. These findings were replicated in
wild type and AS mice. We next wanted to see if this deficit translated into human AS
patients as well. Five human neuro‐typical samples were obtained for testing. Utilizing a
hemoglobin ELISA, samples were examined for blood contamination to determine if the
samples were suitable for further testing. Using human samples which showed no
hemoglobin contamination, we confirmed the presence of UBE3A protein in the human
samples indicating that further investigation is needed. Obtaining human AS CSF
samples is quite difficult due to the rarity of the disorder, although we were very
fortunate to receive three samples with the aid of the Foundation for Angelman
Syndrome Therapeutics (FAST). The first sample, demonstrated a loss of UBE3A
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Figure 3.4.4 Extracellular UBE3A undergoes activity dependent regulation following fear
conditioning.
(A) Western blot quantification of baseline measurements from WT rat hippocampal dialysate, UBE3A
band intensity normalized to revert total protein stain. Representative western blots of UBE3A and revert
total protein stain (n = 7 3M/4F). (B) Control animals placed in the fear conditioning chamber with no
shock or tone applied. Western blot quantification of UBE3A normalized to revert total protein stain and
representative western blots (No shock: 2.0 hr t(15) = 3.028; 2.5 hr t(15) = 2.276; n = 9 6M/3F). (C)
Animals placed in fear conditioning chamber received shock following 1.5 hr habituation to microdialysis
chamber. Western blot quantification of hippocampal dialysate UBE3A levels normalized to revert total
protein stain and representative western blots (Shock: 4.0 hr t(14) = 2.689; 4.5 hr t(13) = 2.436; 5.0 hr t(14)
= 2.632; 5.5 hr t(14) = 2.162; 6.0 hr t(13) = 2.523; 6.5 hr t(14) = 2.365; 7.0 hr t(14) = 3.292; 7.5 hr t(14) =
3.696; n = 8 5M/3F) *P < 0.05, #baseline samples averaged for comparison to time points).
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protein in the CSF by western analysis. Unfortunately, the other two AS samples had
significant levels of hemoglobin and showed positive results on western analysis. This
made it impossible to draw a definitive conclusion on the presence of UBE3A protein
within human AS CSF. Although these results cannot confirm UBE3A protein within the
AS human population, they do demonstrate the presence of UBE3A within neurotypical
human CSF.
Determining the presence of UBE3A within the CSF suggested that UBE3A may
have an as yet unknown extracellular function within the brain. Therefore, we
investigated whether UBE3A protein is present in the extracellular space within the rat
brain. Hippocampal dependent learning and memory deficits are very prominent in AS
making the hippocampus our region of interest. Microdialysis is a technique which
allows for analysis of protein concentration changes within the interstitial fluid in an
awake, free moving animal. This technique has many advantages; each animal serves
as its own control from baseline levels being assessed which means the number of
experimental animals needed is much smaller. We can also collect samples from the
same animal from many different time points and it can be used in many different brain
regions. WT and AS rats were utilized and dialysate was collected every 30 min over an
8 hr period. Samples run on a western blot confirmed the presence of UBE3A protein
within the dialysate, which appeared stable over the 8 hr of sampling (Fig. 4A).
To further implicate UBE3A in having a role in the extracellular space, we sought to
determine if UBE3A maintains its catalytic activity within the interstitial fluid, as well as
the CSF. Ubiquitin ligase activity was observed for both the hippocampal dialysate as
well as the CSF, and as expected ATP was required for the enzyme activity. It has been
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shown that ubiquitin, as well as circulating proteasomes, are located within the
extracellular space in neuro‐typical humans [Sixt & Dahlmann, 2008; Takada et
al., 1997; Wang et al., 1991], suggesting that there may be other functioning E3 ligases
present in our dialysate samples. To determine that the ubiquitination activity is due to
the presence of UBE3A and not other E3 ligases, we used UBE3A immuno‐depletion to
demonstrate that loss of UBE3A protein resulted in ablation of ubiquitin ligase activity.
As could be expected no activity was seen from samples taken from AS rats. Since
UBE3A expression is maintained in glial cells due to paternal gene expression within AS
animals (although at much lower level than in neurons), it seems logical that lack of
extracellular UBE3A in AS rats suggests that the UBE3A secretion is likely from
neurons but this will have to be determined.
Activity‐dependent regulation of UBE3A during learning paradigms could indicate
one aspect of UBE3A's importance in learning and memory. Greer et al. [2010]
previously reported that within primary neuronal culture, following neuronal
depolarization, there was a significant increase in both nuclear and cytoplasmic UBE3A
levels [Greer et al., 2010]. Conversely, if neuronal activity was chemically blocked, there
was a significant decrease in Ube3a mRNA [Greer et al., 2010]. Furthermore, it was
demonstrated that UBE3A expression dramatically changes in a time‐dependent
manner following associative fear conditioned learning, with brain region specific
profiles of expression [Filonova et al., 2014]. It was determined that both the maternal
and paternal allele follow the same expression pattern within each brain region. This
raises an important question; does extracellular UBE3A protein undergo a similar
regulation? We explored this using the same associative fear conditioned learning in
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conjunction with microdialysis. As a control we placed the animals in the fear
conditioning chamber without applying a shock. Interestingly, in the no shock control,
we noticed that immediately after exposure to the fear conditioning chamber, there was
a significant increase in total UBE3A protein. This immediate increase in extracellular
UBE3A rapidly declined within an hour. This was not seen in the group of animals which
were maintained in the microdialysis chamber, which showed no change in baseline
levels. We associated this increase with the experience of being placed in a novel
environment. A previous report demonstrated that exposure to a novel environment
leads to a significant increase in UBE3A expression within the first hour of exposure
[Greer et al., 2010]. Interestingly in rats that were exposed to the full fear conditioning
paradigm, there was a significant increase in UBE3A expression within the extracellular
space at around 2 hr after the shock. This increase in UBE3A was maintained
significantly higher than baseline levels for a longer duration than the increase seen in
animals from the no shock group. This suggests that the more adverse learning
experience had a different and significant effect on UBE3A protein release. The
maintenance of higher levels for longer time may suggest that either an increase in
release or reduction in UBE3A clearance from the extracellular space is occurring.
Although we currently can only speculate on the function of UBE3A protein in the
extracellular space it seems likely that it may have a functional role in consolidation of
more long term memory storage, since the no shock animals had a limited increase in
UBE3A protein. The absence of the immediate increase in UBE3A protein in the shock
group, which was observed in the no shock group, is puzzling and certainly requires
further investigation. This phenomenon was replicated with 8–9 individual animals in
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each group, suggesting an important and significant finding. We can only speculate that
UBE3A regulation may depend on the type of learning, which could be explored using
different cognitive tasks in association with microdialysis. Since we were only able to
test using an aversive stimulus as the conditioning for memory formation, we cannot
exclude the possibility that the alterations in extracellular UBE3A protein expression are
due to the stress and pain, and not necessarily related to the memory formation itself.
Thus further studies of other learning paradigms that do not involve pain/stress would
be of critical importance.
As mentioned above, ubiquitin and proteasomes have been reported being
located in neuro‐typical human serum, plasma, and CSF [Takada et al., 1997; Wang et
al., 1991]. Extracellular ubiquitin has been shown to play a role in many different
pathways, such as being an endogenous agonist of the chemokine receptor CXCR4
which leads to inducing calcium ion influx into the cell. Extracellular ubiquitin can cause
cell differentiation, as well as mediate cell growth and apoptosis [Sujashvili, 2016]. The
source of extracellular ubiquitin is currently unknown, albeit reports have determined
one mode of secretion via T‐lymphocytes inhibiting cytotoxic activity of platelets [Pancre
et al., 1991]. The recent identification of ubiquitin and proteasomes having a role
extracellularly, makes a plausible case for UBE3A having a role outside of the cell. The
only known mechanism of ubiquitination occurs from the ligase pathway implying that
ligases are presumably located in the extracellular space. Reports have demonstrated
that upon neuronal depolarization in primary neuronal cell culture that there is a
decrease in UBE3A membrane localization [Filonova et al., 2014], perhaps suggesting a
release into the extracellular space. UBE3A has also been shown to be associated with
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endomembranes of the Golgi apparatus, presynaptic vesicles and terminals as well as
postsynaptic density [Burette et al., 2017; Burette et al., 2018].
It is still unclear how UBE3A protein is secreted as UBE3A does not contain a
putative secretion sequence. The molecular mechanisms behind UBE3A being secreted
into the extracellular space requires further investigation. The association of UBE3A and
the Golgi apparatus [Burette et al., 2017; Burette et al., 2018; Condon, Ho, Robinson,
Hanus, & Ehlers, 2013] may indicate that UBE3A could go through the conventional
secretory pathway. However, unconventional mechanisms of protein secretion have
been reported, demonstrating that proteins do not have to go through the endoplasmic
reticulum and Golgi apparatus to be secreted [Rabouille, Malhotra, & Nickel, 2012]. One
unconventional pathway involves recruitment of cytoplasmic proteins in vesicular
compartments of the endocytic membrane system which fuse with the plasma
membrane to release proteins into the extracellular space [Dimou & Nickel, 2018].
Interestingly, during microdialysis with the aversive stimulus, the increase in UBE3A
protein is delayed and maintained much longer than in the no shock paradigm. This
could be due to newly synthesized UBE3A protein having to go through the secretory
pathway and ensue transportation to be secreted. This is only speculation although
could potentially be an explanation for the delay in extracellular level changes.
This is the first report, to our knowledge, demonstrating the presence of an E3 ligase in
the extracellular space and so as of now it is unclear what its functional role is.
Demonstrating that extracellular UBE3A is under activity‐dependent regulation leads to
the idea that synaptic receptors could be a potential target. E3 ligases have tight
regulation over learning and memory intracellular components and it is very likely there
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is a similar function in the extracellular space. For example, UBE3A has been shown to
intracellularly target receptors that have major implications in learning and memory such
as the SK2 receptor which has a direct effect of NMDA receptors [Khatri & Man, 2019;
Sun et al., 2015]. Intracellular ubiquitination by E3 ligases other than UBE3A, have
significant impacts on learning and memory, an example being Nedd4 whose role
involves the internalization of AMPA receptors which are critical for synaptic plasticity
[Lin et al., 2011]. To further understand the functioning of UBE3A outside of the cell, our
lab is currently conducting electrophysiological studies and applying exogenous UBE3A
to hippocampal slices. We have identified that long‐term potentiation deficits in AS
slices can be modified with UBE3A protein administration (manuscript in preparation).
UBE3A appears to have diverse and multiple actions with in neurons, with critical
functions within the cytoplasm and nucleus [Avagliano Trezza et al., 2019; Khatri &
Man, 2019]. We believe that this report demonstrates a potential novel role of UBE3A
and supports new perspectives in the current and future studies for potential AS
therapeutics. It is unclear the specific extracellular role(s) for UBE3A, or its implications
in learning and memory but it opens up a new area of investigation for UBE3A. It has
been unclear how the absence of a neuronal “housekeeping” gene, such as UBE3A,
can result in the extent and severity of neuronal dysfunction and disruption in memory
formation. It is becoming increasingly clear that UBE3A is involved in many pathways
with many different functions.
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CHAPTER FOUR:
EXTRACELLULAR UBE3A RECOVERS LTP DEFICITS IN THE AS RAT

4.1 Abstract
We recently generated a novel Angelman syndrome (AS) rat model using CRISPR
to produce a complete Ube3a gene deletion in the rat. We demonstrated that this rat
recapitulates the loss of UBE3A protein throughout the brain and that resulted in cognitive
and EEG deficits. To further characterize the AS rat we explored hippocampal
electrophysiology. It is believed that deficits observed within synaptic plasticity are
translatable to learning and memory deficits demonstrated in behavioral paradigms. Here
we report that the AS rat model demonstrates deficits in hippocampal input/output, longterm potentiation (LTP), and chemically induced long-term depression (LTD). These data
further support the use of the rat model for the study of AS. We also demonstrate that
application of exogenous UBE3A protein to hippocampal slices recovers synaptic plasticity
deficits observed in LTP. These data suggest that extracellular UBE3A protein has an as
yet unexplored functional role in LTP.

4.2 Introduction
Angelman Syndrome (AS) is a severe neurodevelopment disorder affecting
approximately 1:15,000 births (Chamberlain and Lalande, 2010; Maranga et al., 2020;
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Williams et al., 2006). Alterations in the maternally inherited allele of UBE3A (encoding
the E3 ligase termed E6AP) by mis-methylation, mutations or various sized deletions,
leads to the manifestation of AS. The majority of patients present with intractable
seizures, ataxia, cognitive and motor impairments, lack of speech, and notably happy
demeanor with excessive laughter (Clayton-Smith and Laan, 2003; Williams et al.,
2010). Cognitive deficits are prominent in patients, and focusing on the underlying
mechanisms of cognitive disruption and potential therapeutics is a high priority (Bird,
2014; Thibert et al., 2013; Williams et al., 2010).
The predominate AS mouse model was created by an exon 2 null mutation of
Ube3a on chromosome 7. The resulting phenotype revealed a disruption of spatial and
associative memory formation as well as hippocampal synaptic disruption (Jiang et al.,
1998). This AS mouse model is an instrumental tool for understanding altered molecular
pathways leading to the severe AS cognitive deficits and evaluating potential
therapeutics. Specifically the AS mouse model demonstrates severe deficits in memory
formation associated with spatial learning (Morris water maze) and associative fear
conditioning as well as impairments in Schaffer collateral long-term potentiation (LTP)
and long-term depression (LTD) (Jiang et al., 1998; Pignatelli et al., 2014) Synpatic
plasticity changes are mirrored by alterations in both pre- and post- synaptic pathways.
Our collaborative research team recently created a new AS rat model (rUbe3am/p+)

resulting from a full maternal Ube3a gene deletion (Dodge et al., 2020). The

rUbe3am-/p+ rat model displays deficits in learning and memory in behavioral paradigms
such as fear conditioning and touchscreen discrimination (Berg et al., 2020; Dodge et
al., 2020). The rUbe3am-/p+ rats also showed significantly increased cortical and
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hippocampal delta EEG power similar to AS mouse models and humans with AS (Born
et al., 2021). Analysis of epileptiform activity in juvenile and adult rats showed increased
time spent in epileptiform activity and longer time for behavioral recovery from
generalized seizures in AS compared to WT rats (Born et al., 2021). Interestingly, we
have also reported that E6AP is located in the cerebrospinal fluid (CSF) of WT rats,
mice, and neuro-typical humans, but is absent in AS animal models (Dodge et al.,
2021). Furthermore, we demonstrated that E6AP is released into the extracellular space
of the hippocampus where it maintains its catalytic activity and is controlled by dynamic
activity-dependent regulation. This has raised numerous possibilities for the mechanism
of action for UBE3A; specifically if E6AP has a function in the extracellular space or if it
passively secreted for clearance purposes. We hypothesize that extracellular E6AP is
involved in aspects of neuronal function involved in long-term potentiation.
Here we report that the rUbe3am-/p+ rat model demonstrates deficits in
hippocampal input/output, LTP, and chemically induced LTD compared to litter mate
controls. Furthermore, we show that application of exogenous E6AP to hippocampal
slices recovers synaptic plasticity deficits observed in LTP. These data further support
the use of the rat model for the study of AS, and importantly demonstrate that
extracellular E6AP appears to have a significant functional role in LTP.

4.3 Materials and Methods
4.3.1 Animals: UBE3A maternal deletion AS rats (rUbe3am-/p+), described previously
(Dodge et al., 2020). Animals were housed in a standard 12-hour light/dark cycle and
supplied with food and water ad libitum at the University of South Florida, and were
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housed in groups of two per cage. All procedures were conducted in compliance with
the NIH Guidelines for the Care and Use of Laboratory Animals and approved by the
Institutional Animal Care and Use Committee of USF (approval number A4100-01).

4.3.2 Extracellular field recordings: Hippocampal slices were prepared from 4-5 month
old Ube3a maternal deficient rats and their wild-type littermates. Upon euthanasia by
rapid decapitation, brains were rapidly removed and placed in ice-cold oxygenated
(constant perfusion 95% O2/5% CO2) artificial cerebral spinal fluid (ACSF) containing
(125 mM NaCl, 2.5 mM KCl, 26 mM NaHCO3, 1.25 mM NaH2PO4, 25 mM glucose, 1
mM MgCl2, 2 mM CaCl2). Brain slices (400µm) were prepared on a vibratome (Thermo
Scientific Microm HM 650V). Hippocampi were carefully dissected and allowed to
equilibrate to room temperature (23 ± 2 °C) in oxygenated ACSF for approximately 10
min. Slices were then transferred to nylon mesh recording chamber (temperature at
30.2 °C, flow rate 1 mL/min) and allowed to equilibrate for a minimum of 2 hours.
Stimulating electrodes (WPI, TM33CCINS) were placed in CA3 Schaffer collaterals and
field excitatory post synaptic potential (fEPSPs) were recorded from the CA1 stratum
radiatum via glass microelectrodes filled with ACSF (resistance 1-4 mΩ). Hippocampal
area CA1 fEPSPs were recorded using Axon Digidata 1322A interface (Molecular
Devices) data acquisition hardware operated by Axon pClamp 10.0 software. Signals
were amplified with differential amplifier (A-M systems) filtered at 1kHz and digitized at
10kHz. Input/output was determined by stimulating slices from 0 to 15 mV at 0.5 mV
increments. For all experiments, baseline stimulus intensity was set to elicit ~50% of the
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maximum fEPSP response as determined from the input/output curve. LTP was induced
by HFS which consisted of 2 trains of 100Hz stimulation for 1 sec separated by 20sec.
LTD was induced by bathing hippocampal sliced in 100 µM (S)-3,5Dihydroxyphenylglycine (DHPG) for 10 min. For recombinant UBE3A protein
application: following 20min baseline recordings, hippocampal slices were bathed in
recombinant E6AP (Boston Biochem 80nM) for 30 min before undergoing HFS outline
above.
Extracellular field recordings data analysis: Data were analyzed using ClampFit 10.7
software, every 6 sweeps were averaged. Data were normalized to the averaged value
of the initial slope of the fEPSP from the 20 min baseline recording. All data are
represented mean ± SEM. Independent t-test between genotypes (SPSS and
GraphPad) were performed on the last 10 min average following induction method.
Statistical significance was set at p<0.05.

4.3.3 Intracranial injections: Immediately prior to surgery, rats were weighed and
anesthetized with isoflurane. Surgery was performed using a WPI stereotaxic
apparatus. Nocita was used as a localized analgesia (50-100 L at 13 mg/mL). The
cranium was exposed using an incision through the skin along the midsagittal plane,
and 2 holes were drilled through the cranium using a dental drill bit. Using a Hamilton
microsyringe, injections of 3 L of sterile phosphate buffered saline (PBS) or 3 L of 80
nM recombinant E6AP in PBS (Boston Biochem, E3-230) were dispensed bilaterally
into the hippocampus (coordinates from bregma: lateral ±4.5 mm; anteroposterior -6.0
mm; vertical -5.0 mm) using the convection enhanced delivery method described
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previously (Carty et al., 2010). The incision was cleaned and closed with surgical
sutures. Animals were allowed to recover for 20-24h before testing in fear conditioning.
AS mock injected (n=11 (6F/5M)); AS UBE3A injected (n=12 (5F/7M) and wild type
(n=14 (6F/8M) were 3-4 months of age.

4.3.4 Fear conditioning: : Fear conditioning testing was performed on the rUbe3am-/p+
rats as described in detail previously (Dodge et al., 2020). Briefly, the first day of training
consisted of the rats exploring a 25 cm square sound attenuation chamber with a wire
grid floor (Stoelting) for 3 mins prior to the presentation of a 1,000 Hz, 95 dB tone for 30
s and a mild foot shock (1 mA) during the last 2 s of the tone. Freezing was recorded as
a measure of fear and was designated as a lack of movement for 2 consecutive sec by
Ethovision XT soft- ware (Noldus). The second phase consisted of contextual and cued
conditioning, which took place 72 h post-training. AS mock injected (n=11 (6F/5M)); AS
UBE3A injected (n=12 (5F/7M) and wild type (n=14 (6F/8M). Data was assessed for
outliers, by group, prior to analysis using Grubbs outlier test (Alpha = 0.05). One ASMock injected animal was identified and removed from analysis (identified in Figure 6
with △). A one‐way ANOVA followed by a Tukey’s post hoc test was used to analyze
training, cued fear conditioning and contextual fear conditioning. An alpha of 0.05 was
used for all main effects. Results are presented as mean ± SEM. Statistical analysis was
performed using GraphPad Prism software.
4.4 Results
4.4.1 rUbe3am-/p+ deficits in Input/output curve
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Input/output curves were determined prior to LTP induction and were measured
from the slope of field excitatory post synaptic potentials (fEPSPs) elicited by stimuli of
graded intensities. fEPSPs are responses that arise as a manifestation of depolarization
in the CA1 pyramidal neurons. The fiber volley is an indication of the pre-synaptic action
potential arriving at the recording area. The stimulating electrode was placed in the CA3
Schaffer collaterals of the hippocampus while the recording electrode was placed in the
CA1 stratum pyramidale. Figure 1a shows the fiber volley with a significant reduction
with increasing stimulus in the rUbe3am-/p+ rats compared to WT littermates. Figure 1b
demonstrates an equivalent reduction in the fEPSPs with increasing stimulus.
Collectively, there is a significant difference in the input/output curve (Figure 1c) in the
hippocampus of the rUbe3am-/p+ rats compared to the WT.

Figure 4.4.1 Input/output curve reveals reduced hippocampal functional connectivity in AS
maternal Ube3a deficient rats.
a) Fiber volley amplitude with increasing stimulus intensity. b) fEPSP slope during input/output
recordings with increasing stimulus intensity. c) input/output curve comparing slopes of fEPSPs and fiber
volley. (WT n=6 slices n=12, AS n=11 slices n=18)

4.4.2 rUbe3am-/p+ hippocampal LTP deficits
During input/output, the maximum response recorded was used to determine the
stimulus intensity for the remainder of the experiment. Stimulus intensity was set to elicit
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approximately 50% of the maximum response recorded in input/output. This technique
will allow the potential equivalent percentage of LTP despite the reduced rUbe3am-/p+ rat
input/output shown in figure 1. Baseline synaptic transmission was recorded for 20 min
prior to tetanus to ensure a stable response. Following a stable baseline recording, we
next measured changes in fEPSP amplitude over time after high frequency stimulation
(HFS, 2 trains of 100Hz stimulation for 1 sec separated by 20 sec) to evaluate LTP at
Schaffer collateral synapses. Figure 2a demonstrates that the mean values of fEPSP
slopes are significantly decreased in AS rats compared to WT littermates. Figure 2b is
an average of the last 10 min (50-60 min) after HFS demonstrating a significant deficit in
the AS rat compared to WT littermates.

Figure 4.4.2 AS rats have a deficit in hippocampal CA3-CA1 LTP.
a) Slices were maintained at 30.2 ºC and LTP was induced with 2 trains of 100Hz stimulation for 1 sec
separated by 20sec. All results are graphed as the percentage of potentiation standardized to the
baseline recording. Dashed line represents 100% mark of baseline synaptic responses. Data represent
mean ± SEM. (WT n=10 slices n=26, AS n=8 slices n=20). b) Averaged slopes for last 10 minutes (5060min) after HFS (t(10)=85.94, ***p<0.0001).

4.4.3 rUbe3am-/p+ hippocampal LTD deficits
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Following a stable baseline measurement, slices were bathed in 10 µM (S) 3,5
DHPG for 10 min. Following incubation fEPSPs were recorded for 40 minutes following
washout of the DHPG. WT controls show expected synaptic depression stabilizing at
approximately 20 minutes post DHPG application. In contrast there is no detectable
depression in AS rat slices for the duration of the experiment indicating a significant
DHPG-induced LTD deficit in the AS rats compared to the WT rats (Figure 3).

Figure 4.4.3 AS rats have a significant deficit in chemically induced LTD.
a) Following baseline measurements, LTD was induced by (S)3,5-DHPG (10µM) for 10min and fEPSPs
were recorded (average of 6 traces). b) Averaged slopes of fEPSPs for the last 10 min (40-50min) after
LTD induction (WT n=6 slices n=12, AS n=6 slices n=11) t(10)=22.62, ***p<0.0001.

4.4.4 Extracellular E6AP protein rescues rUbe3am-/p+ LTP deficits
We have previously demonstrated that E6AP is present in the extracellular space
and can be detected and quantified using microdialysis (Dodge et al., 2021).
Furthermore, the release of E6AP into the extracellular space was altered in a learning
dependent manner, suggesting that extracellular E6AP may play a role in synaptic
plasticity and memory consolidation or is released in response to neuronal activation.
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Therefore, we set out to determine if supplementation of extracellular E6AP to AS
hippocampal slices could have beneficial effects and rescue of LTP deficits. E6AP
protein (80 nM) was incubated with hippocampal slices from rUbe3am-/p+ rats for 30 min
prior to initiating LTP recordings. We demonstrated that preincubation with E6AP
protein was able to rescue rUbe3am-/p+ slices to the same LTP response observed in
control littermate rats (Figure 4). This corresponded to a rescue of fiber volley indicating
an improvement in presynaptic function (Figure 5A). There also appears to be an
enhanced post synaptic response (increased fEPSP) (Figure 5B). This resulted in an
increase in input/output (Figure 5C). Interestingly, addition of E6AP to WT hippocampal
slices reduced the LTP by ~20% (Figure 4). This was associated with a decrease in
presynaptic activity (decreased fiber volley, Figure 5A), with no significant change in
fEPSP (Figure 5B). This resulted in a reduction in the input/out curve (Figure 5C).
Figure 4.4.4 Exogenous recombinant E6AP protein application recovers CA3-CA1 LTP deficits in

AS rats.
a) Slices were maintained at 30.2 ºC and LTP was induced with 2 trains of 100Hz stimulation for 1 sec
separated by 20 sec following incubation with exogenous E6AP (30 min). All results are graphed as the
percentage of potentiation standardized to the baseline recording. Dashed line represents 100% mark of
baseline synaptic responses. Data represent mean ± SEM (AS n= 8 slices n=20, AS with E6AP n=7
slices n=15). b) Averaged slopes for last 10 minutes (50-60 min) after HFS (t(10)=21.41, ***p<0.0001)
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Figure 4.4.5 Input/output curve with exogenous supplementation of E6AP protein.
a) Fiber volley amplitude with increasing stimulus intensity. b) fEPSP slope during input/output
recordings with increasing stimulus intensity. c) input/output curve comparing slopes of fEPSPs and fiber
volley. (WT n=10 (6F/4M) slices n=12, AS n=8 (6F/2M) slices n=18, WT with Ube3a n=6 (4F/2M)
slices=24, AS with Ube3a n=7 (4F/3M) slices=17)

4.4.5 Extracellular E6AP protein rescues fear conditioned learning and
memory deficits
To assess if exogenous E6AP can have an effect in vivo we tested rUbe3am-/p+
rats with hippocampal injections of E6AP. rUbe3am-/p+ rats were bilaterally injected with
either PBS (AS-Mock) or E6AP (AS-E6AP) and allowed to recover overnight before
training in fear conditioning. A one foot‐shock paradigm followed by a 72 h post‐training
contextual and cued test were utilized for this portion. A control group of wild type rats
was used as a reference. No significant differences were observed during fear
conditioning training in any of the groups. However, as expected at 72 h post‐training,
the AS-Mock injected rats had deficits in both cued and contextual fear conditioning
compared to WT animals (Figure 6A&B), which was consistent with what we have
reported previously (Dodge et al., 2020). Surprisingly, AS-E6AP injected animals
showed a rescue in contextual fear conditioning compared to AS-Mock injected animals,
with AS-E6AP rats performing similar to WT rats (Figure 6A). Hippocampal injection of
E6AP did not rescue the cued deficit as might be expected because this is more
amygdala dependent (Figure 6B).
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Figure 4.4.6 Exogenous recombinant E6AP protein injection into AS rat hippocampi recovers
hippocampal dependent learning and memory.
a) Contextual fear conditioning test shows rescue of AS deficit with E6AP injection (F(2, 34)=21.32,
P<0.0001). b) Cued fear conditioning shows no change with E6AP protein injection (F(2,33)=13.03,
P<0.0001). AS mock injected (n=11 (6F/5M)); AS UBE3A injected (n=12 (5F/7M)) and wild type (n=14
(6F/8M)). No significant differences were found between sexes. Statistics: One Way ANOVA, Tukey
post-hoc test,***p≤0.0005, ****p<0.0001, Δ= outlier identified by Grubbs test.

4.5 Discussion
The rUbe3am-/p+ rat offers a new and potentially complementary model to
explore disease mechanisms or therapeutic interventions; however, this model has yet
to be fully characterized, specifically with the focus on synaptic plasticity. It is
hypothesized that memories are formed from persistent strengthening and weakening of
synaptic connections in the form of LTP and LTD. Support for this has come through
occlusion studies, determining that synaptic plasticity in the hippocampus is required for
memory formation. Hippocampal electrophysiology for these studies was designed to
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establish the specific phenotype for this new model and use a true gene deletion model
to better understand the role of Ube3a deficiency on the molecular mechanisms
underlying hippocampal synaptic function.
Input/output curves are a reliable method for quantifying overall synaptic
transmission following a single stimulation of varying intensity. This curve nicely
represents presynaptic function from measurements of the fiber volley and can correlate
to post synaptic activation through the measurement of the slope of the fEPSP. There
are inconsistent reports utilizing the Ube3a exon 2 null mutation mouse model as to
presence or extent of an input/output deficit (Ciarlone et al., 2016; Ciarlone et al., 2017;
Egawa et al., 2012; Jiang et al., 1998; Judson et al., 2016; Moreira-de-Sa et al., 2020;
Pignatelli et al., 2014; Rotaru et al., 2018), but all agree there are synaptic deficits in
LTP. Here we show that the rUbe3am-/p+ rats have a significant deficit in the fiber
volley and fEPSPs with respect to WT rats. This result suggests that the rUbe3am-/p+
rat CA3-CA1 functional connectivity is lower. This could possibly be due to the reduced
number of functional synapses within the Schaffer collaterals or an overall deficit in
molecular mechanisms controlling synaptic function. Numerous altered pathways,
pertinent to normal cognitive functioning, have been reported in the AS mouse model
(El Hokayem et al., 2018; Lopez et al., 2017; Sun et al., 2015). This leads the idea that
the culmination of many dysfunctional pathways leads to such severe deficits in both
pre- and post-synaptic mechanisms. This rUbe3am-/p+ rat model may offer a better
model for investigating functional connectivity demonstrating a more prominent deficit in
input/output.
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LTP is a measure of synaptic plasticity thought to mimic mechanisms underlying
memory formation and consolidation (Sah et al., 2008). LTP is broken down into three
phases with the early phase heavily relying on kinase activity and the later phases
depending on protein synthesis and remodeling/strengthening of synapses. LTP deficits
are a hallmark phenotype in the AS null mutation mouse model (Jiang et al., 1998).
Here, we demonstrate a significant LTP deficit in the rUbe3am-/p+ rat model in both
initiation and maintenance. There are many reports in the AS mouse giving us insight
into potential mechanisms that could be altered leading to the manifestation of the
significant deficit we are seeing in the rUbe3am-/p+ rat (Khatri and Man, 2019; Lopez et
al., 2018). A significant report demonstrated, in the AS mouse model, proper
calcium/calmodulin-dependent protein kinase II (CaMKII) signaling is required for earlyphase NMDA receptor-dependent LTP induction and maintenance. Sites of CaMKII
autophosphorylation in the AS mouse are shown to be altered leading to altered CaMKII
regulation manifesting as LTP deficits (Weeber et al., 2003). SK2 receptors are
regulators of NMDA receptor function and have been reported to be direct targets of
E6AP ubiquitination. Deficits in Ube3a leads to increased SK2 levels directly impacting
NMDAR activation consequently impairing LTP (Sun et al., 2015). While additional
dysfunctional learning and memory pathways have been reported in the AS mouse
model, these few examples give insight into how the loss of Ube3a can lead to severely
altered LTP.
LTD is necessary for forming new memories by reducing the efficacy of neuronal
synapses. LTD makes it possible for the continuation of forming new memories. If
synapses were not able to remodel and reduce strength, a threshold could be created
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inhibiting the creation of new connections and therefore new memories. LTD is thought
to be the result of a decrease in presynaptic neurotransmitter release and a decrease in
postsynaptic receptor density all of which heavily relies on dendritic protein synthesis
(Huber et al., 2000; Waung and Huber, 2009). LTD responses in the AS mouse have
been complex. Pignatelli et al. (2014) have reported with in the hippocampus that
compared to WT mice, AS mice show no differences with low-frequency stimulation
(LFS; 1 Hz 15 min) but interestingly show enhanced LTD with DHPG (Pignatelli et al.,
2014). This increase was not affected by the NMDA antagonist AP5. Others have
reported that AS mice show an increased sustained LTD response to LFS, which could
be corrected with the SK2 selective blocker Apamin (Sun et al., 2015). Contrary to this,
it has been reported that 3 trains of 1500 pulses at 2 Hz for 10 min actually results in a
deficit of LTD for the AS mice, which can be corrected with the A2AR selective
antagonist SCH58261 (Moreira-de-Sa et al., 2020). Yashiro et al. (2009) showed a loss
of LTD by LFS in the neocortex of AS mice compared to WT (Yashiro et al., 2009). Here
we demonstrate deficits in the AS rat model with administration of DHPG compared to
WT rats. The activity of E6AP to target proteins to the proteasome as well as target
portions of the proteasome itself (Yi et al., 2017) and the fact that proteasome
functioning is a major component in synaptic plasticity (Dong et al., 2008; Ehlers, 2003),
suggests that alterations in the proteasome could potentially be an underlying
pathophysiology leading to AS deficits in synaptic plasticity. In support of this Pignatelli
et al. showed different response to LTD with the proteasome inhibitor UBE1-41, in AS
compared to WT mice (Pignatelli et al., 2014). The report here of a DHPG-induced LTD
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deficit establishes the AS rat model as a potential future tool for better understanding
the molecular mechanisms of synaptic depression with Ube3a deficiency.
Extracellular ubiquitin is a relatively new finding and is poorly understood. With
the few studies that have been conducted, it is becoming clear that extracellular
ubiquitin has major implications in normal functioning. Extracellular ubiquitin has been
reported to play roles in modifying cell differentiation and apoptosis, moderating platelet
cytotoxicity and most notably receptor internalization and induction of calcium influx
(Sixt and Dahlmann, 2008; Sujashvili, 2016). We have previously demonstrated the
presence of E6AP within the extracellular space in both CSF and hippocampal
interstitial fluid in the rat (Dodge et al., 2021). Extracellular E6AP maintained its catalytic
activity towards both itself, as well as a well-known substrate, S5A. Furthermore,
extracellular E6AP was shown to be under activity-dependent regulation following fear
conditioning. Interestingly in rats that were exposed to the fear conditioning paradigm,
there was a significant and sustained increase in the release of E6AP into the
extracellular space. Although we currently can only speculate on the function of E6AP in
the extracellular space it seems likely that it may have a functional role in consolidation
of more long term memory storage, as no shock animals had a limited increase in E6AP
(Dodge et al., 2021). We wanted to further investigate if E6AP plays a role in learning
and memory from the interstitial fluid, therefore, we applied exogenous E6AP to
hippocampal slices just prior to LTP induction. We observed a significant rescue of the
LTP deficits in the AS rats, such that they were not significantly different from WT LTP
levels. More surprisingly, we observed that intra-hippocampal injection of E6AP could
rescue contextual fear conditioning deficits. This is a noteworthy finding demonstrating
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that extracellular E6AP has the ability to correct synaptic plasticity deficits from the
extracellular space, suggesting a novel function for E6AP.
Interestingly, administration of E6AP to WT hippocampal slices appeared to
reduce the amplitude of the LTP. This may suggest a dose dependent effect for
extracellular E6AP. An examination of a dose response in AS hippocampal slices may
inform more on this. Increased E6AP is known to cause a related neurodevelopmental
disorder Dup15q. Dup15q is caused by a duplication of a portion of 15q11.2-13.1
chromosome which results in clinical symptoms similar to those observed in AS but
typically lack the severe ataxia seen in AS (DiStefano et al., 2020; LaSalle et al., 2015).
This duplication results in a duplication of the UBE3A gene, however, the pathogenic
role of increased UBE3A levels in Dup15q syndrome has not been definitively proven
and other genes in this chromosomal region could be contributing. It has been
demonstrated that increased gene dosage of Ube3a results in glutamatergic synaptic
transmission suppression as a result of reduced presynaptic activity and postsynaptic
action potential coupling. We appear to also observe a decrease in the presynaptic
response in wild type slices incubated with the exogenous E6AP. Further exploration of
extracellular E6AP in Dup15q mouse models may contribute to our understanding of
E6AP’s involvement in LTP in both of these diseases.
Demonstrating the recovery of LTP deficits through exogenous E6AP application
raises numerous questions. It is unclear how E6AP is released into the extracellular
space let alone how it is interacting with receptors or other extracellular proteins to
modulate learning and memory. Given that we have previously observed activitydependent regulation of extracellular E6AP (Dodge et al., 2021), we might speculate
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that E6AP is ubiquitinating synaptic receptors to alter their efficacy or activation. Of
course one could speculate that exogenous administration of E6AP to hippocampal
slices could affect intracellular proteins if the protein is actively taken up, but we feel that
it is more likely to affect proteins extracellularly in the short incubation time of 30 min.
Our data suggests that extracellular E6AP is affecting both presynaptic and post
synaptic responses in the rUbe3am-/p+ hippocampal slices, with restoration of fiber
volley and enhancement of fEPSP (Figure 5). The mechanism of the enhanced fEPSP
in the rUbe3am-/p+ slices is a mystery and future work should also explore both pairedpulse facilitation and effects of E6AP on LTD.
We believe that this study demonstrates that the rUbe3am-/p+ rat is a promising
model that will complement the existing mouse model for the study of synaptic plasticity
deficits in AS. Overall the rUbe3am-/p+ rat model demonstrates significant deficits in
synaptic plasticity and functional connectivity. These deficits are very severe and
presumably contribute significantly to the deficits in cognition that we have observed
previously (Berg et al., 2020; Dodge et al., 2020). The functional significance of
extracellular E6AP has yet to be fully explored but certainly expands our understanding
of the role of E6AP on LTP. E6AP has previously been identified in both the cytoplasm
and nucleus, with different isoforms showing different distributions (Burette et al., 2017;
Burette et al., 2018; Sirois et al., 2020; Zampeta et al., 2020). This study adds to the
complexity of E6AP and suggests that E6AP may have functional activities within
different cellular locations with in neurons.
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CHAPTER FIVE:
CONCLUDING REMARKS AND FUTURE DIRECTIONS

The exon 2 Ube3a null mutation AS mouse model has been at the center of AS
research for well over a decade (Jiang et al. 1998). This model has presented with
notable challenges such as strain influences, phenotypic inconsistencies, and interlaboratory discrepancies (Huang et al. 2013; Born et al. 2017). There is a high demand
for a single AS model that consistently recapitulates the majority of phenotypes seen
within the human AS population. Advancements in rat genetic manipulation technology
has allowed scientists to create models for preclinical research retaining a high degree
of genetic conservation relative to humans. Due to the advancements in CRISPR/Cas9,
we have successfully created a full maternal UBE3A deletion rat model (Dodge et al.
2020). Western blotting of brain and peripheral tissues indicates a complete loss of
Ube3a within the CNS, and approximately a 50% reduction in peripheral tissues.
Generally, four major phenotypes found in AS have been focused on when studying
potential therapeutics for AS: motor learning and coordination, learning and memory,
synaptic plasticity, and seizures. In chapter two, we presented the behavioral
characterization of the new AS rat model we generated. This rat model demonstrates a
robust phenotype with motor and cognitive impairments. Locomotor aberrations were
seen in hind limb clasping, rotarod, and DigiGait. The AS rats also showed a significant
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deficit in learning and memory tasks with deficits in both cued and contextual fear
conditioning. We also observed deficits in social interaction. Unlike the AS mouse
model, the AS rats do not show a significant increase in weight although still
demonstrate a deficit in locomotor tests. This elucidates that both the AS mouse and rat
models most likely demonstrate these deficits due to an ataxic phenotype and not
weight gain (Dodge et al. 2020).
Our collaborators have further investigated this model and demonstrate
significant deficits, further displaying the translatability of this rat model to the human AS
population. It was reported that AS pups across early development have a decrease in
vocalization and was reproduced in two independent laboratories. Their results further
demonstrated deficits in motor coordination with AS rats showing a deficit in vertical
activity during all age groups as well as deficits in rotarod. AS rats also had deficits in
adhesive tap removal being slower to initiate removal and slower to finish the removal.
Utilizing touchscreen discrimination, AS rats illustrate a robust learning and memory
impairment (Berg et al. 2020).
Thus far, this novel AS rat model recapitulates many of the human AS
phenotypes: learning and memory, motor learning and coordination, and social deficits.
Further characterization is needed in areas such as seizure propensity, EEG readings,
and sleep cycle studies. Due to the rat model more closely mimicking the human in
sleep pathophysiology, demonstrating higher levels of melatonin, this model is
promising for further investigation of altered sleep pathways (Ebihara et al. 1986;
Roseboom et al. 1998; Stehle, von Gall and Korf 2002; Korf, Von Gall and Stehle 2003;
Stehle, von Gall and Korf 2003). Seizures are one of the most severe, and understudied
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phenotypes in AS ( Thibert et al. 2009; Laan et al. 1997; Pelc, Cheron and Dan 2008).
The established literature on mouse behavior promotes the C57Bl/6 background strain
be used for comparison to other studies. A major caveat with this background strain is
the audiogenic seizure phenotype is non-existent (McLin, Thompson and Steward
2006). The C57Bl/6 background strain has also been reported to be resistant to kainite
induced seizures (Schauwecker 2000). Determining seizure propensity in the AS rat
would greatly aid in studying pathophysiology and potential therapeutics.
Synaptic plasticity is hypothesized as being responsible for long term memory
formation and consolidation. Deficits in learning and memory behavioral paradigms led
us to investigating long-term potentiation (LTP) and long-term depression (LTD). The
AS rat model had a significant deficit in the input/ouput curve which is most likely
indicative of a presynaptic deficit. Many reports have demonstrated presynaptic deficits
in the AS mouse model which appear to be recapitulated in the AS rat model.
Furthermore, the AS rat displays significant deficits in both LTD and LTP. These deficits
further support the utilization of this model for investigating AS. In the AS mouse model
it has been demonstrated that LTP deficit can be recovered with overstimulation
suggesting an increased threshold to synaptic plasticity exists (Weeber et al. 2003). The
AS mouse model has demonstrated alteration in receptor levels as well as alterations in
both pre- and post-synaptic molecular mechanisms important in synaptic plasticity.
Further investigation on synaptic plasticity deficits is needed to determine if the same
pathways observed in the AS mouse model are altered in a similar manner.
The AS rat model has already made a major contribution to furthering our
understanding of UBE3A function. While utilizing this model for biomarker analysis, we
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are the first to report UBE3A is located within the CSF of WT rats and not in AS rats.
We have also confirmed UBE3A is present in human and mouse CSF, although due to
blood contamination we were not able to definitively conclude if there is a robust
difference between AS and neuro-typical humans. It is very difficult to obtain human AS
CSF samples albeit further testing is necessary to determine the efficacy of UBE3A as a
potential biomarker. Determining UBE3A as a biomarker would not only assist in
diagnosis, it would also aid in therapeutic testing being a significant outcome measure.
Learning and memory deficits are very prominent within human AS patients as
well as AS rodent models (Jiang et al. 1998; Williams, Driscoll and Dagli 2010).
Following the discovery that UBE3A is located within the CSF, we wanted to see if
UBE3A is located within the extracellular space of the hippocampus. Microdialysis not
only revealed that UBE3A is within the hippocampal extracellular space, but that UBE3A
is also under dynamic activity-dependent control. Following fear conditioning there was
an increase in extracellular UBE3A levels which were maintained much longer than the
no shock controls. The maintenance of higher levels for longer time suggests that either
an increase in release or reduction in UBE3A clearance from the extracellular space is
occurring. It seems likely that it may have a functional role in consolidation of more long
term memory storage, since the no shock animals had a limited increase in UBE3A.
This data implicates UBE3A potentially having a novel role within the extracellular
space.
To further implicate extracellular UBE3A having an extracellular function, we
applied exogenous UBE3A to AS hippocampal slices before inducing LTP. Surprisingly,
there was a recovery in the AS LTP deficit to WT levels. Determining the recovery of
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LTP deficits through exogenous UBE3A application raises numerous questions. We
would firstly like to determine if application of extracellular UBE3A extends from
synaptic plasticity to recovery of behavioral deficits. Microdialysis offers many
advantages one being the direct infusion of drugs to targeted brain regions in an awake,
fully functioning animal. This would allow us to infuse the extracellular space with
UBE3A during microdialysis in conjunction with fear conditioning to determine if the
behavioral deficits mentioned in chapter two, could be recovered.
In future studies we would like to elucidate the mode of secretion. As mentioned
in chapter 3, there are many avenues for unconventional secretion. UBE3A does not
contain a putative secretion sequence indicating the use of an unconventional pathway.
Furthermore it is of high interest to determine how extracellular UBE3A is modifying key
components in learning and memory. Determining proteins and receptors UBE3A is
interacting with as well as pathways altered with UBE3A, would significantly advance
our understanding in how the loss of UBE3A, a “housekeeping” gene, can have such
devastating consequences.
Activating the paternal allele is a promising therapeutic target for human AS
patients. It is unclear if the paternal allele can express all of the isoforms with the same
functions as its maternal counterpart. Investigation of paternal UBE3A secretion is
necessary to determine if the paternal allele could potentially have the same functions
as the maternal. Another promising therapeutic target is gene therapy. Similarly, we
would like to determine if this mode of UBE3A enhancement would follow the same
secretion mechanisms.
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In summary, we have created an AS rat model that recapitulates many of the
phenotypes in human AS. We believe that this model will help advance research into
AS. We are also the first to show that UBE3A appears to have an extracellular
functional role in synaptic plasticity and memory. This will open up a new area of
investigation into the mechanism of disease as well as offer up potential new targets for
therapeutic intervention.
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